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ABSTRACT 
Engineering Microbubbles with the Buried-Ligand Architecture 
for Targeted Ultrasound Molecular Imaging 
Cherry Chen Chen 
 Microbubbles are gaseous microspheres stabilized with phospholipid monolayer shells.  
Because of their compressible gas core, they are highly echogenic.  Taking advantage of this 
property, microbubbles are used as ultrasound contrast agents for signal enhancement.  In 
addition, they are being developed for targeted diagnostic molecular imaging applications.  
Previous studies have shown that targeted microbubbles could induce complement activation and 
reduce their circulation persistence.  In order to avoid the undesired immune response, a novel 
stealth microbubble design that consisted a bimodal poly(ethylene glycol) (PEG) brush layer, 
named buried-ligand architecture (BLA), was introduced.  However, in order to utilize this BLA 
design for targeted imaging, it is essential to characterize the kinetics of ligand conjugation to 
BLA microbubbles and further study their in vitro and in vivo immunogenicity and contrast 
persistence properties. 
In this project, ligand conjugation to BLA microbubbles was characterized using 
molecules with large molecular weight difference.  Microbubbles with various PEG surface 
architectures were formulated, and ligands with large molecular weight difference were used to 
conjugate to the microbubbles in order to study the feasibility of generating targeted 
microbubbles using the post-labeling technique.  It was shown that small ligands could be 
conjugated to BLA microbubbles to generate targeted contrast agents using post-labeling.  A 
surprising result was observed during the experiment that complex surface microstructures could 
be induced simply through streptavidin-biotin binding.  This was the first time that these 
wrinkled structures were generated on the surface of microbubbles using a non-mechanical 
method. 
In vitro immunogenicity studies showed that BLA microbubble indeed induced less 
complement activation than microbubbles with monomodal PEG brush layers, or exposed-ligand 
architecture (ELA) microbubbles.  In vivo contrast persistence studies further demonstrated the 
improved circulation time of the BLA microbubbles and showed that the buried-ligand design 
did not compromise their ability for signal enhancement.  The results presented in this project 
supported the previous findings that microbubbles with the buried-ligand architecture had 
reduced immunogenicity with prolonged circulation persistence and were more suitable to be 
developed for targeted molecular imaging applications. 
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Chapter 1: Introduction 
 
1.1. A Historical Perspective 
1.1.1. The Discovery of Microbubbles 
Merriam-Webster dictionary defines the word “bubble” as “a small globule body of gas 
within a liquid”.  Microbubbles typically refer to gas-in-liquid emulsions with diameters ranging 
between 0.5-100 µm.  Dilute air microbubbles occur in natural waters, and can be remarkably 
stable for hours, or even days (D'Arrigo 2003).  The existence of naturally occurring 
microbubbles has been demonstrated in fresh water (Dean 1944), sea water (Johnson and Cooke 
1981) and even blood and other body fluids (Harvey, Whiteley et al. 1944) by many 
investigators over the last century.  These stable suspensions are topics of great concern to 
scientists and engineers in many fields with profound practical importance.  In waste-water 
treatment, small microbubbles are required to efficiently separate colloidal pollutants from water 
during microflotation (Cassell, Kaufman et al. 1975; D'Arrigo 2003).  In marine biology, the 
presence of bubbles in the near-surface region of the ocean has great significance over a number 
of oceanographic processes, such as converting organic carbon to particulate form through 3).  In 
meteorology, air bubbles produced by breaking waves carry surface-active organic materials 
upon rising to the ocean surface and eject them into the air in the form of aerosols upon breaking 
and, therefore, affect the local air quality and rain formation (Blanchard 1975; D'Arrigo 2003).  
Among technological applications that utilize high power ultrasound, acoustic cavitation (the 
inertial collapse of a microbubble) is widely accepted as the main effector that determines the 
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efficiency of processes such as ultrasonic cleaning (Pohlman, Werden et al. 1972; Zeqiri, Gelat 
et al. 2003). 
Indeed, microbubbles have a wide range of importance across many scientific fields.  The 
origin of their long lasting stability, therefore, becomes the next important topic for scientists and 
engineers to study.  The theory of microbubble surface stabilization was proposed in the early 
1900s.  Langmuir and Adam showed that a clean water surface, if left standing without cover, 
would soon be covered by a monomolecular organic layer (Langmuir 1917; Fox and Herzfeld 
1954).  Fox and Herzfeld proposed that these organic molecules, such as fatty acids, 
spontaneously encapsulate naturally occurring air bubbles in fresh water and serve as stabilizing 
agents as the bubbles are compressed (Fox and Herzfeld 1954).  Experimental work done by 
Johnson and Cooke using photomicrography to observe the dissolution of microbubbles in 
seawater revealed that some bubbles did not dissolve completely; instead, “they stopped 
decreasing in size abruptly, sometimes becoming slightly aspherical, and remained as 
microbubbles apparently stabilized by films compressed during dissolution” (Johnson and Cooke 
1981; D'Arrigo 2003).  It was suggested that “some mechanical or diffusion-limiting effect that 
resists further bubble dissolution is activated during bubble contraction and the attendant 
compression of encapsulating surface films” (Johnson and Cooke 1981).  Biochemical analysis 
of the surfactant found on natural microbubbles showed that it is mainly, if not all, composed of 
hydrophobic paraffinic lipids and glycoproteins that are partial degradation products of 
biological  origin (D'Arrigo 2003).  Interestingly, the surfactant systems widely used today for 
microbubble encapsulation in many industrial and biomedical applications are designed to be 
composed of similar materials, attempting to mimic the natural process of microbubble 
formation. 
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 Microbubbles are currently used in a large scope of industrial and technological 
applications.  As mentioned earlier, microbubbles are used in microflotation for wastewater 
treatment because of their large surface area and relatively slow rise velocities (Cassell, Kaufman 
et al. 1975; Kojima 2010).  As microbubbles rise in wastewater, they come into contact with 
organic pollutants and other low-density particulates and carry them to the surface to form a 
collective foam layer for subsequent separation and purification processes.  In the mineral 
industry, fine particles are separated from solutions using microbubbles in a similar fashion 
called electroflotation (Kraizman 1974).  Electroflotation is a simple process that floats particles 
to the surface of a water body by microbubbles of hydrogen and oxygen gases generated from 
water electrolysis (Chen 2004).  Because of the high surface-area-to-volume ratio, microbubbles 
are ideal for mass and energy transfer.  In the bioprocessing industry, yeast biomass production 
mainly depends on the oxygen transfer efficiency of the aeration system carried out by 
microbubbles (Ago, Nagasawa et al. 2005).  In the pharmaceutical industry, bioreactors require 
microbubble aeration systems to carry out similar air/oxygen mass transfer (Zimmerman, Tesar 
et al. 2008).  In the more recent years, microbubbles have received increasing attention for 
biomedical applications.  In the next section, a detailed developmental history of microbubbles 
as ultrasound contrast agents for diagnostic imaging is reviewed. 
 
1.1.2. The Development of Ultrasound Contrast Agents for Diagnostic Imaging 
 The clinical use of microbubbles as ultrasound contrast agents originated with a chance 
discovery by a cardiologist, Dr. Claude Joyner, in the late 1960s (Gramiak and Shah 1968; 
Cosgrove and Harvey 2009).  While performing an M-mode echocardiogram, he noticed a 
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transient increase in ultrasound signal in the aortic root each time an injection of saline solution 
was made via a cardiac catheter (Becker and Burns 2000; Kaufmann, Wei et al. 2007; Cosgrove 
and Harvey 2009).  Subsequent research revealed that it was the free air bubbles, either 
suspended in the saline solution or formed at the tip of the catheter during the injection, not the 
liquid itself, responsible for the observed echo-enhancement.  This exciting discovery initiated 
new investigations and the development of contrast enhanced ultrasound over the next several 
decades, and it ultimately led to the commercial exploitation of microbubbles as ultrasound 
contrast agents for diagnostic imaging applications. 
 Initial experiments with contrast agents relied on intracoronary injections of hand-
agitated or low-energy sonicated free air bubbles to produce myocardial enhancement 
(Kaufmann, Wei et al. 2007).  However, these techniques typically involved toxic chemical 
compounds such as hydrogen peroxide to generate the microbubbles (Kemper, Oboyle et al. 
1983; Feinstein, Tencate et al. 1984).  In addition, they were limited by the wide size range of 
microbubbles produced and the potential for large bubbles to be trapped within the 
microcirculation (Becker and Burns 2000; Kaufmann, Wei et al. 2007).  In order to improve 
microbubble biocompatibility, reproducibility and clinical feasibility, attention was turned 
towards the development of stabilized microbubbles with diameters less than 10 µm in order to 
ensure the free passage of the contrast agents through the heart and pulmonary capillary network.  
High-energy sonication was utilized in an attempt to improve the size distribution.  However, the 
microbubbles produced, typically from iodinated radiopaque contrast agents, were shown to 
acutely alter the hemodynamics, and their short persistence time still did not allow for 
intravenous administration (Gillam, Kaul et al. 1985; Moore, Smucker et al. 1986; Lang, Borow 
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et al. 1987).  Figure 1.1 illustrates how a bolus injection of microbubble contrast agents may be 
used to assist the diagnosis of myocardial diseases during contrast echocardiography. 
 
 
Figure 1.1.  Left ventricular cavity opacification using microbubble contrast agents.  (A) View of 
the left ventricle (LV).  (B) The same view after a bolus injection of Imagent microbubble contrast 
agent.  The left ventricle (LV), endocardial border (LV/ENDO) and papillary muscle (PAP) are 
clearly seen after microbubble injection, which allows myocardial thickening to be evaluated.  
When watching the heart in motion, normal functioning heard muscle thickens as it contracts, 
while abnormal heart muscle moves less and does not thicken.  Taken from Schutt et al. (Schutt, 
Klein et al. 2003). 
 
 Surfactant encapsulated microbubbles dramatically advanced the contrast agent research 
field by solving many of the issues associated with stability and size distributions.  The challenge 
was first met in 1984 by Feinstein et al. (Feinstein, Shah et al. 1984), who produced stable 
microbubbles by sonicating a solution of human serum albumin and showed through direct 
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microscopic visualization that they could pass through the capillary vasculature unhindered, 
similar to red blood cells, after a peripheral venous injection.  This agent was subsequently 
developed commercially into Albunex (Molecular Biosystems, Inc., San Diego, CA), the first 
product approved by the US Food and Drug Administration (FDA) for use in the United States.  
A list of examples of commercially available contrast agents is presented in Table 1.1. 
 
Table 1.1. Reported doses for commercially available microbubble contrast agents 
      
Concentration 
(mL-1) 
Mean 
Diameter 
(μm) 
Recommended 
Dose† Name Shell Material Gas 
Albunex Albumin Air 3.0-5.0 x 108 3-5 15-20 mL 
Definity Lipid Perfluoropropane 1.2 x 1010 1.1-3.3 10 μL/kg BW* 
Echovist Galactose Air 200-300 mg 2 3.0-10.0 mL 
Imagent Lipid surfactant Perfluorohexane 5.9-13.7 x 108 6+ 6.25 μL/kg BW* 
Levovist Galactose/Lipid Air 200-400 mg 2 6.5-19.5 mL 
Optison Albumin Perfluoropropane 5.0-8.0 x 108 3.0-4.5 0.5-3.0 mL 
Sonazoid Lipid Perfluorobutane 1.2 x 109 3+ 15 μL/kg BW* 
SonoVue Lipid Sulfur hexafluoride 2.0 x 108 3 2.0-2.4 mL 
* Per kilogram of body weight 
+ Based on volume-weight, all other mean diameters are expressed as number-weight 
† Bolus intravenous injection into peripheral vein 
 
 
 
Modern, first-generation contrast agents still used air as the core gas.  These air bubbles 
were surrounded by a fatty acid, lipid, or protein shell (Miller, Averkiou et al. 2008).  The 
encapsulating shell increased the stability of the microbubbles both in the vial and during 
circulation.  In addition to Albunex, other commercially available first-generation contrast agents 
included Echovist (SH U454; Schering AG, Berlin, Germany) and Levovist (SH U508 A; 
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Schering AG, Berlin, Germany), both of which were microcrystalline galactose microspheres, 
with improved formulation made for Levovist using palmitic acid coating for further stabilization.  
Both Echovist and Levovist were only available in Europe, Canada and part of Asia for Doppler 
enhancement of the liver, kidney and heart.  The other uses of Echovist and/or Levovist were in 
contrast sonography in gynecology to assess uterus abnormalities (Becker and Burns 2000; 
Quaia 2005; Greis 2008; Miller, Averkiou et al. 2008). 
 One of the problems with “first generation” microbubbles was the limited persistence and 
efficacy after intravenous injections (Miller, Averkiou et al. 2008).  Because of the inherent 
unsaturation of dissolved gasses in blood owing to alveolar ventilation-perfusion mismatch 
(Gattinoni, Carlesso et al. 2011), the air contained within these microbubbles readily diffused out, 
resulting in a very short half-life (~1 min) and the inability to produce sufficient ultrasound 
contrast for most diagnostic applications (Quaia 2005).  In order to solve this problem, “second 
generation” contrast agents utilized inert gases with low solubility and diffusivity, such as 
perfluorocarbons and sulfur hexafluoride gas (SF6).  These microbubbles retained their gas core 
for a longer period of time.  Thus, the duration of contrast enhancement was increased from 
several seconds to several minutes (van Liew and Burkard 1995; Miller, Averkiou et al. 2008).  
Table 1.2 lists the solubilities and diffusivities of several commonly used inert gases for the 
stabilization of the second-generation microbubble contrast agents. 
Optison (FS-069; GE Healthcare, Princeton, NJ) obtained approval from the FDA for 
echocardiography in 1998 as the first second-generation (non-air) contrast agent.  As with 
Albunex, Optison also contains human serum albumin as the encapsulating microbubble shell, 
but it uses perfluoropropane gas, instead of air, for the gas core.  The relatively insoluble gas is 
inert and eliminated through normal gas exchange in the lung (Schutt, Klein et al. 2003).  
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Optison was shown to opacify the left ventricular chambers at doses much smaller than Albunex 
(0.5-3 mL compared with 15-20 mL, respectively) and for a much longer period of time (>5 min 
compared with 30-45 seconds, respectively) (Quaia 2005; Miller, Averkiou et al. 2008). 
 
Table 1.2. Critical characteristics of various filling gases used for microbubble stabilization 
(Schutt, Klein et al. 2003; Borden and Dayton 2008; Borden, Qin et al. 2010) 
Gas Gas Solubility in Water (25 ⁰C) (mol/m3) 
Gas Diffusivity in Water 
x 106 (cm2/s)* 
Nitrogen (N2) 0.63 20 
Perfluorobutane (n-C4F10) 0.021 6.9 
Perfluorohexane (n-C6F14) 2.7 x 10-4 5.8 
Perfluoropropane (n-C3F8) 0.19 7.7 
Oxygen (O2) 1.32 21 
Sulfur Hexafluoride (SF6) 0.27 6.7 
* For N2 and O2, data is measured at 25 ⁰C; for all other gases, data is measured at 20 ⁰C 
 
 
Definity (MRX-115, DMP-115; Lantheus Medical Imaging, North Billerica, MA) is 
another agent that uses perfluoropropane as the gas core for contrast enhancement.  But this 
agent uses a monolayer of phospholipids as the shell material for stabilization.  It requires a 45-
second mechanical agitation for activation in a dental amalgamator.  Small volumes of these 
microbubbles opacify the left ventricular chamber and enhance the Doppler signal from the 
peripheral vasculature for prolonged periods of time (Kitzman, Goldman et al. 2000).  The 
microvascular rheology of Definity has been shown to be similar to that of red blood cells in 
circulation (Miller, Averkiou et al. 2008), and the gas elimination routes and shell metabolism is 
believed to be similar to Optison (Borden, Qin et al. 2010).  Definity was the first lipid-coated 
second-generation contrast agent approved by the FDA for echocardiography and in Canada and 
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part of Europe for liver and kidney imaging.  More recently, Definity obtained its approval for 
echocardiography in India, Australia, New Zealand, parts of the Pacific Rim and several 
countries in the Middle East. 
A similar contrast agent, Imagent (AFO-150; IMCOR Pharmaceuticals, San Diego, CA), 
also contains a perfluorocarbon gas core (perfluorohexane) to increase its in vivo circulation 
persistence.  It similarly uses phospholipids as the encapsulating shell together with other water-
soluble structural agents, buffers and salts (Quaia 2005).  Like the other two approved agents, 
Imagent was approved by the FDA in 2003 and is indicated only for echocardiography. 
Although not approved for sale in the United States, SonoVue (BR-1; Bracco Imaging, 
Amsterdam, the Netherlands) is also a second-generation contrast agent approved for use in 
Europe, Canada and Asia.  SonoVue uses SF6 as the stabilizing gas surrounded by a flexible 
phospholipid shell.  The uniformity of the microbubble diameter improves its backscattering and 
harmonic behavior at low acoustic power insonation (Gorce, Arditi et al. 2000; Quaia 2005).  
SonoVue was originally approved by the European Union medical agency in March 2001 for a 
broad range of indications, including echocardiography, vascular Doppler enhancement and 
assessment of vascularity of focal lesions in liver and breast (Greis 2008).  However, it was later 
issued a warning statement that extra caution should be exercised in patients with conditions 
such as severe hypotension, cardiac arrest and myocardial infarction (Miller, Averkiou et al. 
2008).  Currently, SonoVue is under clinical trials in the United States for contrast-enhanced 
ultrasound imaging of multiple organs, including focal liver and breast lesion characterizations 
(Greis 2008). 
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Another similar agent that is still under clinical trials in Europe and the United States is 
Sonazoid (NC100100; GE Amersham, Oslo, Norway).  Sonazoid consists of lipid-coated 
microspheres that are stabilized with perfluorobutane gas.  Similar to SonoVue, it also has a 
well-defined size distribution with a volume-weight median diameter of approximately 3 µm 
(Quaia 2005; Sontum 2008).  Japan is the first country that approved Sonazoid injections for 
contrast enhanced diagnosis of hepatic tumor.  In addition, Sonazoid is currently being tested for 
myocardial perfusion imaging.  Preclinical data revealed that Sonazoid was almost exclusively 
internalized by Kupffer cells during late phase after injection, suggesting a potential liver-
specific entrapment strategy for targeted ultrasound imaging (Quaia 2005). 
The second generation contrast agents combined two principle ways of increasing 
microbubble stability and persistence in the peripheral circle: external encapsulation with 
surfactants and selection of gases with low solubility and diffusion coefficient.  A third 
generation of contrast agents is currently being developed to engineer the microbubble shell to 
impart unique functional features to these contrast materials.  Currently, several agents have 
already reached to their late stages of the initial preclinical testing, once again signaling an 
exciting advancement of the development of modern ultrasound contrast agents. 
BR-14 (Bracco Research SA, Geneva Switzerland) is a phospholipid-stabilized third-
generation contrast agent that uses perfluorobutane gas to produce persistent contrast 
enhancement of tissue perfusion even at low power insonation (Quaia 2005).  Initial experiments 
attributed this prolonged persistence to the transient microbubble retention within the capillaries 
(Fisher, Christiansen et al. 2002), and an early phase I study showed promising results for safety 
and efficacy in assessment of liver and kidney perfusion (Basilico, Blomley et al. 2002). 
11 
 
 
CARDIOsphere (PB-127; Point Biomedical Corp., San Carlos, CA) is composed of a 
bilayer shell made up of polylactide polymer and human albumin (Miller, Averkiou et al. 2008).  
The polylactide inner layer is a biodegradable polymer that governs the acoustic behavior of the 
microbubble, while the albumin outer layer ensures the biocompatibility of the agent.  The 
microspheres are filled with nitrogen gas and are designed to collapse under very specific 
ultrasound conditions.  Once destroyed, the nitrogen gas quickly dissolves into the surrounding 
blood, and this rapid loss of gas produces an intense signal that can be detected using low power 
imaging techniques (Leong-Poi, Song et al. 2002). 
Microbubbles with targeting ligands attached to the surface also belong to the third 
generation of contrast agents that are currently being developed for diagnostic imaging 
applications.  Adhesion molecules are added to the contrast agent shell so that the microbubbles 
will adhere to a specific region expressing biomarkers along the vascular endothelium.  
Targeting ligands, such as monoclonal antibodies, peptides and polysaccharides, can be 
incorporated into the shell of the microbubbles to provide selective adhesion to the biomarkers 
expressed on the endothelium (Borden, Qin et al. 2010).  After injection into the bloodstream, 
the contrast agents accumulate via adhesion receptors at the targeting site, providing echo-
enhancement for detection.  Research in targeted ultrasound contrast imaging has evaluated 
many molecular biomarkers associated with intravascular pathology, including tumor 
angiogenesis, thrombosis and inflammation (Lanza and Wickline 2001; Borden, Qin et al. 2010).  
A detailed introduction to targeted ultrasound molecular imaging is provided in Section 1.4.  To 
date, although several research groups have produced initial results, no human clinical studies 
have been performed. 
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1.2. Physicochemical Properties of Microbubbles 
1.2.1. Microbubble Fabrication 
 Various methods have been developed to generate microbubbles for ultrasound imaging.  
The most popular method has been emulsification by entrainment of a gaseous core into the 
aqueous phase by mechanical agitation at the gas-liquid interface (Borden, Qin et al. 2010).  
Both shaking (amalgamation) and sonication techniques fall into this category.  These techniques 
can produce microbubble suspensions rapidly (on the order of tens of seconds) with relatively 
high concentration and a polydisperse size distribution, ranging between sub-micrometers to tens 
of micrometers in diameter. 
 The acoustic behavior of contrast agents is strongly affected by their size (Gorce, Arditi 
et al. 2000; Sirsi, Feshitan et al. 2010; Streeter, Gessner et al. 2010).  For both diagnostic 
imaging and therapeutic applications, a high degree of control over the size and uniformity of the 
microbubble suspensions is required in order to achieve the highest level of contrast 
enhancement, to ensure accurate dosing of a given drug and to maximize delivery efficiency.  
Moreover, as more advanced imaging techniques are developed, which exploit the complex 
nonlinear features of the microbubble signals in order to enable quantification of tissue perfusion 
and molecular biomarker expression, the ability to predetermine the acoustic response of a 
microbubble suspension is becoming increasingly important (Stride and Edirisinghe 2009).  
Consequently, a number of new methods have been developed to improve the control over 
microbubble size and other characteristics. 
One way to control microbubble size is to size fractionate a pre-formed microbubble 
suspension using flotation (Kvale, Jakobsen et al. 1996).  This separation method takes 
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advantage of the buoyant nature of the microbubbles.  More recently, following the same 
governing principles, Feshitan et al. developed a size fractionation technique using differential 
centrifugation to rapidly select microbubble subpopulations based on size (Feshitan, Chen et al. 
2009).  Figure 1.2 compares the images of initial polydisperse and final size-isolated 
microbubbles using differential centrifugation technique in both bright field and epi-fluorescence 
mode.  While size fractionation methods require additional steps after microbubble generation to 
reduce the polydispersity of the samples, the method is relatively straightforward and results in 
high microbubble yields.  Other more sophisticated techniques have been developed to produce 
monodisperse microbubbles, including flow focusing (Talu, Hettiarachchi et al. 2008), T-
junction (Xu, Nie et al. 2005), ink-jet printing (Bohmer, Schroeders et al. 2006) and coaxial 
electrohydrodynamic atomization (CEHDA) (Stride and Edirisinghe 2008).  These techniques 
mainly utilize microfluidic processing methods to generate microbubbles with narrow size 
distributions.  However, they require more complicated equipment setup in comparison to the 
sonication method and have much lower microbubble production rate in terms of processing time. 
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Figure 1.2. Microscopy images of initial polydisperse and final size-isolated microbubbles using the 
differential centrifugation technique in both bright field (left) and epi-fluorescence (right) mode.  
Freshly made microbubble suspensions are highly polydisperse (A, B).  Size isolation allows rapid 
selection of microbubble subpopulations based on their diameters (4-5 μm C, D and 1-2 μm E, F).  
Taken from Feshitan et al. (Feshitan, Chen et al. 2009). 
 
There are many ligand attachment strategies to conjugate targeting molecules to the 
monolayer shell of the microbubbles (Klibanov 2005; Klibanov 2009).  However, all strategies 
may be grouped in two major approaches: pre- and post-labeling.  The formal approach referred 
to as pre-labeling involves coupling the targeting ligand to the shell-forming molecule, typically 
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lipid molecules, in a separate procedure.  This strategy offers the ability to fully control the 
synthesis and purification of targeted microbubbles in a step-by-step manner, ensuring high 
product yield and purity.  The latter approach, referred to as post-labeling, requires the 
incorporation of functionalized lipids into the microbubble shell, and the targeting ligands are 
conjugated to the monolayer surface through either covalent bonds or non-covalent interactions 
after the microbubbles have been formed.  This technique increases the efficiency of attaching 
targeting ligands, since not all lipid molecules in the original liposomal mixture are incorporated 
into the microbubble shells.  This is particularly true for size-selected microbubbles using the 
differential centrifugation method (Feshitan, Chen et al. 2009).  Instead of having a ligand 
attached to all lipid molecules, one can calculate the amount of ligand needed for conjugation 
based on the microbubble concentration, the size distribution, and the area fraction of 
functionalized lipids of the microbubble suspension, thereby reducing the cost of synthesis.  
Post-labeling also increases versatility by allowing multiple ligands to be conjugated to the same 
microbubble batch.  This platform strategy for targeted contrast agent production is expected to 
increase safety, economy, and ease-of-use, when compared to pre-labeling. 
 
1.2.2. Microbubble Monolayer Shell Properties 
1.2.2.1. Surface Architectures 
 Microbubble shells are typically composed of two major components: an amphiphilic 
phospholipid species and a poly(ethylene glycol) (PEG) derivatized emulsifier (Figure 1.3).  The 
surface architecture refers to the internal structure of the PEG brush layer on the microbubble 
shell, which depends on both lipid composition and shell microstructure (Borden, Qin et al. 
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2010).  The incorporation of the PEGylated lipid into the shell enhances microbubble stability, 
and this stabilizing effect depends on the amount of PEG chains and their confirmations on the 
surface (Needham, Zhelev et al. 1999).  Similar to the design of long-circulation liposomes, it is 
commonly believed that the brush layer of PEG chains can form a steric barrier against 
coalescence and adsorption of macromolecules to the microbubble surface (Klibanov, Maruyama 
et al. 1990; Klibanov 1999).  This protective role of PEG is assumed to be due to the steric 
hindrance effect of the polymer brush; each PEG chain forms an impermeable “cloud” over part 
of the microbubble surface, which inhibits other molecules from diffusing into the brush layer 
(Torchilin, Papisov et al. 1995; Needham, Zhelev et al. 1999).  Needham et al. (Needham, 
Zhelev et al. 1999) showed that small PEG mushrooms could retard the binding of fluorescently 
labeled avidin to biotinylated liposomes.  As the PEG concentration increased, the overall vesicle 
fluorescence intensity decreased, indicating that the binding of avidin was retarded or even 
completely prevented due to the presence of PEG.  Kuhl et al. (Kuhl, Leckband et al. 1995) also 
showed using a surface force apparatus (SFA) that the dominant force that stabilized liposomes 
with short polymer chains grafted on the surface was steric repulsion.  Repulsive thermal 
fluctuation forces swamped short-ranged van der Waals attraction and longer-range electrostatic 
interactions, and provided a physical barrier around the bilayer to prevent close approach of 
other surfaces, improving liposome in vivo circulation persistence through reduction in 
opsonization and vesicle aggregation. 
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Figure 1.3.  Cartoon illustrating the PEG polymer brush on the lipid monolayer shell of a 
microbubble. 
 
 For targeted contrast agents, the targeting ligands are normally attached to the distal end 
of the PEG chains, where the polymer can be extended beyond the average brush layer height to 
allow the ligand to efficiently bind to its target.  However, targeting ligands typically present 
chemical groups (e.g., nucleophiles such as hydroxyl groups) that could trigger immune 
activation and decrease microbubble circulation persistence.  Thus, a useful structure may be a 
bimodal mixture of grafted PEG chains: a fraction of shorter PEGs bearing targeting ligands and 
a fraction of longer PEGs without ligands to minimize undesired immune complement activation 
and nonspecific adhesion (Borden, Sarantos et al. 2006; Borden, Zhang et al. 2008). 
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1.2.2.2. Tethered Ligand-Receptor Interactions in a Bimodal Polymer Brush Layer 
 The structure and molecular interactions of bimodal polymer mixtures have been widely 
studied both theoretically (Birshtein, Liatskaya et al. 1990; Lai and Zhulina 1992; Dan and 
Tirrell 1993; Chen and Dormidontova 2005; Longo, Thompson et al. 2008) and experimentally 
(Dhoot, Watanabe et al. 1994; Levicky, Koneripalli et al. 1998; Goedel, Luap et al. 1999; Kim, 
Klibanov et al. 2000; Moore and Kuhl 2006; Kuhlman, Taniguchi et al. 2007).  Using a 
numerical self-consistent field model, Dan and Tirrell (Dan and Tirrell 1993) showed that 
vertical segregation between the segments of the shorter and longer polymer chains occurred 
irrespective of the molecular weight differences or composition in a bimodal polymer brush layer.  
When two bimodal polymer surfaces were compressed, this stratification persisted.  Lai and 
Zhulina (Lai and Zhulina 1992) used Monte Carlo simulations to further confirm the segregation 
of the free ends of longer and shorter chains.  They also showed that the structural properties of 
the shorter chains depended very little on the lengths of the longer chains when both were highly 
stretched. 
 Experimentally, Kim et al. (Kim, Klibanov et al. 2000) showed in a force microscopy 
experiment that adhesion to avidin-coated glass beads failed when biotin ligands were tethered to 
short PEG chains buried in a longer PEG overbrush.  In addition, they showed proof that the 
presence of a spacer moiety could improve the effective interaction range of a ligand past the 
steric barrier created by PEG chains into a partially obscured binding site, supporting a similar 
finding made by Wong et al. (Wong, Kuhl et al. 1997) using bilayer surfaces.  Borden et al. 
reported similar results, in which specific adhesion of microbubbles with a bimodal polymer 
brush was partially prevented in hydrodynamic conditions in comparison to microbubbles with a 
monodisperse polymer brush layer (Borden, Sarantos et al. 2006).  These results indicated that 
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ligand accessibility could be reduced when targeting ligands are attached to the shorter PEGs in a 
bimodal mixture of PEG chains, therefore reducing undesired potential immune response and 
nonspecific adhesion. 
 
1.3. Microbubbles as Ultrasound Contrast Agents 
1.3.1. Acoustic Behavior of Microbubbles 
1.3.1.1. Microbubble Scattering and Resonance 
 The high echogenicity of microbubbles comes from their compressible gas core.  It has 
low density and high compressibility, allowing it to expand and contract in response to the 
application of an ultrasound field (Borden and Dayton 2008).  As a result, microbubbles undergo 
volumetric oscillation (pulsation) (Figure 1.4) and consequently scatter much more energy than 
solid or liquid spheres of the same size (Stride and Saffari 2003).  Fortuitously, the resonance 
frequency of a microbubble able to pass through human capillaries (<7 μm) lies within the 
acoustic bandwidth of typical diagnostic scanners (1-10 MHz), meaning that the amplitude of 
microbubble oscillations (and hence the scattering effect) is thus maximized (Stride and Saffari 
2003; Borden and Dayton 2008; Borden, Qin et al. 2010).  A resonant microbubble is a thousand 
times more echogenic than a non-resonant microbubble of the same diameter (Calliada, Campani 
et al. 1998).  Due to this high degree of backscatter in comparison to blood and surrounding 
tissues, Klibanov et al. demonstrated that it was possible to detect individual microbubbles 
(~0.004 pL gas volume) with a clinical ultrasound system (Klibanov, Rasche et al. 2004). 
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Figure 1.4. Radius-time streak image of a microbubble oscillating in response to an acoustic 
pressure field.  The transmitted pulse is shown in yellow, and the predicted microbubble radius-
time curve is shown in red.  Taken from Ferrara et al. (Ferrara, Pollard et al. 2007). 
 
 A unique aspect of microbubble acoustic behavior is that they expand to a greater degree 
than they can be compressed (McCulloch, Gresser et al. 2000; de Jong, Emmer et al. 2009).  
Depending on the peak negative pressure (PNP) of the incident ultrasound beam, the scattering 
behavior of microbubbles may be linear or nonlinear (de Jong, Emmer et al. 2009).  For low 
acoustic pressure exposure, the instantaneous radius of a microbubble oscillates linearly in 
relation to the amplitude of the applied external ultrasound pressure field.  As the pressure is 
increased, the pulsation of the microbubbles starts to show nonlinear characteristics, returning 
echoes not only at the fundamental frequency but also at multiples of the resonance frequency 
(i.e. harmonics).  As the pressure if further increased, microbubble destruction can occur, 
resulting in the release of the encapsulated gas into the immediate environment.  While tissues 
can also produce echoes that are rich in harmonic frequencies, substantial differences in the 
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pressures and frequencies associated with harmonic spectra allow microbubble and tissue echoes 
to be differentiated.  The resulting “harmonic imaging” improves the signal-to-noise ratio, 
optimizing visualization of the contrast agent population (McCulloch, Gresser et al. 2000). 
 
1.3.1.2. Microbubble Attenuation 
 In the case of dilute microbubble suspensions, the power of the backscattered signal is 
proportional to the contrast agent concentration (de Jong, Hoff et al. 1992).  Therefore, a local 
increase in blood volume is reflected by an increase in contrast agent concentration, which can 
be quantified by measuring the increase of backscattered power (Stapleton 2007).  However, 
above a certain concentration threshold, microbubble attenuation becomes significant, and the 
backscattered power will no longer increase linearly with concentration (de Jong, Hoff et al. 
1992).  It becomes difficult, therefore, to perform quantitative contrast flow measurements at 
high microbubble concentrations.  A clear indication of microbubble attenuation is the 
shadowing effect observed during imaging, in which the underlying structure is obscured after a 
high concentration microbubble injection (Figure 1.5). 
 Microbubble attenuation is due to viscous, thermal and radiation damping effects as the 
microbubbles oscillate (Stapleton 2007).  The total attenuation as ultrasound passes through a 
bubbly medium is the sum of absorption and scattering.  For microbubbles oscillating below 
their resonant frequencies, attenuation is dominated by absorption; while for microbubbles 
driven above their resonance, attenuation is dominated by scattering (Stapleton 2007). 
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Figure 1.5.  Illustration of the shadowing effect caused by microbubble attenuation.  (A) Prior to 
the administration of microbubbles, the underlying structure below the mouse kidney was visible 
(arrows).  (B) A 100 µL bolus injection of 4-5 µm size-isolated microbubble samples was made.  
Significant shadowing was observed in the mouse kidney as a result of microbubble attenuation.  
The underlying structure under the kidney was completely obscured.  Courtesy of Dr. Shashank 
Sirsi. 
 
1.3.1.3. Effect of Ultrasound Radiation Force on Microbubbles 
 When a traveling ultrasound wave is absorbed by a particle, the momentum associated 
with the wave produces a net primary radiation force in the direction of the ultrasound wave 
propagation (Nyborg 2006).  For compressible objects, such as microbubbles driven at their 
resonant frequency, they experience far larger radiation forces than their incompressible 
counterparts.  Dayton et al. (Dayton, Allen et al. 2002) showed that using low-amplitude 
resonant frequency ultrasound pulses of many cycles, microbubbles could be physically pushed 
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over distances on the order of millimeters.  Therefore, it is possible to force contrast agents 
circulating in the blood pool into contact with targeting sites on the endothelium under a specific 
ultrasound field.  Assuming that the great majority of microbubbles and targets will reside in the 
capillaries, it may be sufficient to displace the contrast agents only a few microns in order to 
facilitate binding (Zhao, Borden et al. 2004).   In addition, using intravital microscopy, Dayton et 
al. (Dayton, Klibanov et al. 1999) demonstrated that microbubbles traveled at a reduced velocity 
when concentrated near the vessel wall in comparison to those in the center of the flow system, 
allowing more contract time for ligand-receptor bond formation. 
 For ultrasound contrast agents, the effect of the radiation force is maximized when 
microbubbles are driven at their resonance frequencies.  For a typical microbubble that can pass 
through microvasculature freely without being trapped and cause embolism, its resonance 
frequency lies within 1-10 MHz.  However, for small animal imaging, high frequency is 
normally desired to achieve higher spatial and temporal resolution.  Therefore, there is a great 
need to develop an imaging transducer that can offer dual-frequencies for improved small animal 
imaging: one at low MHz range to physically manipulate the microbubbles by pushing them 
against the endothelium and one at high MHz range for contrast enhanced imaging. 
 In addition to the primary radiation force, secondary radiation force has been reported to 
affect microbubble populations as well.  When two neighboring microbubbles oscillate in an 
ultrasound field, both of these vibrating gas bodies generate additional sound fields of the same 
frequency, and each of them serves as both source and receptor of an attractive secondary 
radiation force (Nyborg 2006).  Photographic evidence of bubble clustering as a result of 
secondary radiation forces has been reported as early as 1975 by Crum (Crum 1975).  More 
recently, Dayton et al. (Dayton, Morgan et al. 1997; Dayton, Allen et al. 2002) confirmed the 
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occurrence of clustering and found good agreement between the predicted and measured speeds 
of approach of neighboring microbubbles.  Interestingly, the clusters were found to be resistant 
to separation during insonification even at low pressures.  But they dispersed as soon as 
transmission was stopped.  Thus, the effects of secondary radiation forces were only found to be 
significant at high pulse repetition frequencies (Stride and Saffari 2003). 
 For a low-amplitude resonant frequency pulse that is currently used for clinical 
ultrasound imaging, the oscillation of the microbubbles could expose the targeting ligands on the 
surface of BLA microbubbles to initiate site-specific binding.  However, current clinical 
ultrasound systems are not yet designed to produce the necessary pulse sequences to utilize 
radiation force enhanced targeting.  There are still great needs to design a new generation of 
ultrasound transducers with optimized acoustic parameters to selectively activate stealth 
microbubbles and to enhance their targeting abilities for molecular imaging. 
 
1.3.2. Safety 
 The safety of diagnostic microbubbles is a complex issue because not only must their 
safety as drugs be studied, but additionally, the effects of sonication also need to be taken into 
consideration (Cosgrove and Harvey 2009).  The constituents of microbubble contrast agents, 
including the shell materials and the core gas, are carefully chosen to their biological inertness 
and have passed numerous stringent safety tests.  The acoustic power needed during contrast-
enhanced ultrasound is well characterized using mechanical index (MI) to guide the clinical 
usage of microbubbles, in order to minimize any potential bioeffects due to the interaction of 
ultrasound waves with the gas bodies, such as inertial cavitation.  A detailed introduction to 
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potential microbubble immunogenicity is provided in Section 1.3.3.  In this section, the results 
from several multicenter studies regarding the safety of contrast agents in clinical settings are 
reviewed. 
 A multicenter Italian study retrospectively checked the records of 23,000 patients who 
had been studied for liver lesions using contrast-enhanced ultrasound and found only 29 adverse 
events, of which two were severe enough to require treatment (Cosgrove and Harvey 2009).  The 
adverse event rate was only 0.0086%, and no deaths were reported.  The adverse events were 
hypotensive reactions occurring within 2 min after injection, and were treated successfully by 
standard resuscitation techniques.  A more recent American retrospective study compared over 
4,300,000 patient records for acute mortality (death occurring within 24 hr after injection) 
showed that no increase in acute mortality resulted due to the injection of contrast agents (Main, 
Ryan et al. 2008).  No statistical significance (P = 0.61) was detected between patients who 
underwent non-contrast echocardiography studies (24-hr mortality rate = 1.08% with n = 45,789 
deaths) and patients who underwent contrast-enhanced studies (24-hr mortality rate = 1.06% 
with n = 616 deaths).  These findings suggested that the deaths related to contrast-enhanced 
ultrasound simply resulted from “pseudo complication”, the progression of the underlying 
disease (Main, Ryan et al. 2008).  In light of these large scale clinical safety studies, the FDA 
relaxed the restrictions and warnings on the use of contrast agents in 2008.  However, the basic 
safety principles of weighing the possible risks against the potential benefits for contrast agent 
injection should still be practiced for each patient.  Nevertheless, physicians using or controlling 
the use of microbubble contrast agents must be familiar with standard resuscitation techniques 
and have the appropriate monitoring and rescue apparatus to hand (Cosgrove and Harvey 2009). 
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 There is numerous compelling evidence of the efficacy of microbubble contrast agents to 
support the notion of their usage for diagnostic ultrasound imaging.  However, microbubbles are 
currently only approved in the United States for cardiology imaging (Wilson, Greenbaum et al. 
2009).  The major concern involved in the clinical approval of microbubbles used for noncardiac 
imaging is the potential anaphylaxis reaction to these agents.  The current project is to address 
this very issue by engineering a stealth microbubble design in the attempt to minimize their 
potential immunogenicity while keeping other targeting properties for molecular imaging 
applications. 
 
1.3.3. Microbubble Immunogenicity 
1.3.3.1. Introduction to the Complement Immune System 
 The complement system, consisting of over 30 soluble plasma and cell-surface bound 
proteins, is an important effector arm of both innate and adapted immunity (Murphy, Travers et 
al. 2008).  There are three pathways to activate the complement system: the classical pathway, 
the lectin pathway and the alternative pathway.  The classical pathway is triggered by the binding 
of complement component C1q to immune-complexes on the antigen surfaces; the lectin 
pathway is triggered by the binding of mannose-binding lectin to arrays of carbohydrates on 
foreign microorganisms; and the alternative pathway is triggered by the binding of spontaneously 
activated complement component C3 in plasma to the surface of foreign particles.  All three 
pathways converge to the formation of C3 convertases, which cleave C3 into C3b and C3a for 
further opsonization and mediation of inflammation in the complement cascade.  Figure 1.6 
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shows the crystal structure of complement component C3 obtained using x-ray diffraction with 
the location of its surface active thioester bond pointed out. 
 There are also three ways in which the complement system initiates subsequent responses 
once it is activated.  First, it generates a large number of activated complement proteins that bind 
covalently to pathogens, opsonizing them for engulfment by phagocytes (i.e., priming).  Second, 
the small fragments of some complement proteins act as chemoattractants and anaphylatoxins 
(e.g., C3a) to recruit more phagocytes to the site of complement activation, and also to activate 
these phagocytes.  Third, the final components in the complement pathway form the membrane 
attack complex to create pores in the pathogen membrane. 
One key site for the activation of the complement system is the surface of foreign 
particles (Murphy, Travers et al. 2008).  Regardless of the activation pathway, the main effectors 
of the complement system (such as C3 convertases and C3b) need to bind to the surface of the 
particle in order to initiate the phagocytic process.  Therefore, the accessibility of the 
complement component proteins to the foreign particle surface, or rather to the specific 
recognition sites on the surface, is important in determining complement activation. 
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Figure 1.6.  Crystal structure of complement component C3 with the location of its surface active 
thioester bond pointed out by arrow.  Adapted from Janssen et al. (Janssen, Huizinga et al. 2005). 
 
1.3.3.2. Microbubble Immunogenicity 
When administered intravenously, microbubbles or other conventional colloidal particles 
are rapidly removed from the bloodstream by the mononuclear phagocyte system (MPS) 
(Mosqueira, Legrand et al. 2001).  Previous studies have shown that the biodistribution of 
microbubbles was substantially different as compared to free lipids or liposomes (Tartis, Kruse et 
al. 2008).  They are mainly retained by the liver, spleen and lungs (not the kidneys) shortly after 
injection, and this rapid uptake is attributed to the Kupffer cells and macrophages of the MPS 
(Walday, Ostensen et al. 1994; Walday, Tolleshaug et al. 1994; Perkins, Frier et al. 1997; 
Willmann, Cheng et al. 2008). 
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Walday et al. (Walday, Tolleshaug et al. 1994) studied the biodistribution of radiolabeled 
Albunex in both rats and pigs up to 90 min after intravenous administration and found that about 
60% of the albumin microspheres were recovered in the liver, 9% of them were recovered in the 
spleen, and 5% of them were recovered in the lungs 3 min after injection in rats.  In contrast, in 
pigs, more than 90% of the microbubbles were recovered in the lungs, and this was explained by 
the presence of intravascular macrophages in the porcine lungs (Walday, Tolleshaug et al. 1994).  
Using commercially available targeted microbubbles, MicroMarker (Bracco Research; Geneva, 
Switzerland), labeled with radioactive antibodies specific to VEGFR2, Willmann et al. 
(Willmann, Cheng et al. 2008) showed similar results that rapid accumulation in both liver and 
spleen were detected using tumor mice models.  He also showed that a small amount of targeted 
microbubbles were accumulated in the mouse kidneys, which could be due to VEGFR2 
expression in normal renal tissue rather than non-specific adhesion. 
The MPS protects the systemic circulation by distinguishing foreign and endogenous 
substances, and the fast clearance of foreign particles is mediated through endocytosis with 
recognition of specific cell surface receptors, such as complement receptor 1 (CR1) and Fc 
receptor (Harashima, Sakata et al. 1994; Murphy, Travers et al. 2008).  Endocytosis is classified 
into three categories: receptor-mediated endocytosis (RME), pinocytosis and phagocytosis 
(Lodish, Berk et al. 2008).  Depending on the size of the particle, it can be eliminated from the 
system either through RME and/or pinocytosis (for small compounds) or phagocytosis (for large 
particles such as microbubbles).  Evidence of microbubble phagocytosis has been demonstrated 
both in vitro (Yanagisawa, Moriyasu et al. 2007) and in vivo (Quaia, Blomley et al. 2002; Lim, 
Patel et al. 2004).  Although not required, phagocytosis is often triggered by specific receptor 
recognition, and such ligand-receptor interactions typically exist between the cellular receptor 
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specific for the proteins bound to the colloidal particles rather than for the particles themselves.  
Thus, serum protein adsorption is extremely important in determining particle uptake by 
phagocytes and predicting the fate of colloidal particles after administration.  Immunoglobulin G 
(IgG) and complement components are known as major opsonins for the uptake of large particles, 
such as bacteria, viruses, and remnants of dead cells.  In particular, complement activation plays 
a critical role in the recognition of microbubbles by the immune system (Szebeni 2005). 
For targeted contrast agents, the targeting ligands conjugated to the surface typically 
present nucleophilic groups (e.g., hydroxyl and amino) that could trigger the alternative pathway 
of the complement activation cascade and decrease microbubble circulation persistence.  Clinical 
reports have shown data indicating that long circulating PEGylated liposomes, with similar 
surface structures to microbubbles, could trigger acute hypersensitivity reaction in sensitive 
individuals (Szebeni 2005; Szebeni 2005).  These reactions are classified as complement 
activation-related pseudoallergy (CARPA) due to their common trigger mechanism: complement 
activation (Szebeni 2005; Moghimi, Andersen et al. 2010).  Despite the common belief that 
water-soluble PEG chains on the surface of Stealth liposomes can prevent immune recognition 
by reducing protein adsorption and vesicle aggregation, recent studies have suggested that 
PEGylated liposomes are capable of triggering the complement system in human serum and 
fixing opsonic complement proteins (Moghimi and Szebeni 2003; Szebeni 2005; Moghimi, 
Hamad et al. 2006; Moghimi and Hamad 2008).  It was reported that complement activation was 
detectable as quickly as 10 min after injection of the marketed liposomal drug Doxil (Centocor 
Ortho Biotech Inc.; Horsham, PA) (Szebeni 2005), which is on the same time scale as 
microbubble persistence in vivo.  The reason behind the long circulation of PEGylated liposomes 
while they are associated with complement activation is still not fully understood.  One 
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hypothesis is that the surface grafted PEG chains inhibit the accessibility of complement surface 
fixation and thus prevent the ligation to complement receptors (Borden, Qin et al. 2010).  
Therefore, it is important to design targeted microbubbles with a surface architecture that 
minimizes complement recognition by minimizing C3/C3b fixation, in order to reduce CARPA 
and prevent premature microbubble clearance from the circulatory system.  At the same time, 
avoidance of complement fixation can keep the ligand pristine and, therefore, allow it to retain 
specificity to the target receptor. 
 
1.4. Targeted Ultrasound Molecular Imaging 
1.4.1. Introduction to Targeted Ultrasound Molecular Imaging 
 Molecular imaging is an emerging field that aims to visualize, characterize and measure 
biological processes at the molecular and cellular levels in humans and other living systems.  
This new discipline seeks to represent the individual molecular events in order to understand the 
molecular basis of the disease and to develop drugs directed at those molecular targets (Mancini, 
Greco et al. 2009).  Targeted ultrasound molecular imaging utilizes contrast-enhanced ultrasound 
with labeled microbubbles that are engineered specifically to target molecular biomarkers that 
are associated with intravascular diseases (Figure 1.7).  Furthermore, microbubbles could carry 
therapeutic drugs that can be released to the targeted sites upon injection.  Therefore, targeted 
ultrasound molecular imaging may provide potential therapeutic implications over other 
traditional imaging modalities. 
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Figure 1.7.  Cartoon illustrating targeted microbubbles binding to specific biomarkers along the 
endothelium during circulation for molecular imaging applications. 
 
 There are two major approaches to promote targeting of microbubbles to a specific region 
of interest in vivo: passive targeting and active targeting (Mancini, Greco et al. 2009).  The 
former approach takes advantage of inherent chemical or electrostatic properties of the 
microbubble shell, leading to the adhesion of microbubbles along the endothelium.  This method 
relies on the non-specific binding between microbubbles and endothelial receptors that are up-
regulated due to disease.  It allows for functional imaging of the pathophysiological condition 
that induces the over-expressed cell surface biomarkers, although it does not exhibit molecular 
specificity.  The latter method, referred as “active targeting”, takes advantage of the 
functionalized contrast agents with targeting ligands deliberately attached to the surface.  The 
targeting ligand binds to specific receptors along the endothelium, resulting in the accumulation 
of targeted contrast agents to disease sites and allowing a quantitative measurement of the 
expression of these molecular biomarkers.  Since the microbubbles remain within the vasculature 
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because of their micron size, specific marker molecules have to be located in the intravascular 
space.  For instance, intercellular adhesion molecule-1 (ICAM-1) that is up-regulated during 
atherosclerosis can be used as targeted markers for ultrasound molecular imaging. 
 The protocol used for targeted ultrasound molecular imaging may be different from what 
is followed for regular ultrasound imaging procedures (Dayton and Borden 2008; Mancini, 
Greco et al. 2009) (Figure 1.8).  After a bolus injection of targeted contrast agents, a 4-15 min 
dwell time is allowed before starting the contrast enhanced imaging.  This wait time serves two 
purposes: first, it allows the retention of adhesive microbubbles at the target site; second, it 
allows for the clearance of freely circulating (non-adherent) contrast agents, which would 
otherwise interfere with the detection of the targeted agents.  Microbubbles accumulated at the 
target site are imaged using a destruction-subtraction algorithm.  Typically, a background image 
is recorded first, and a 2-3 sec breaking pulse with high mechanical index (MI) is then applied to 
remove all the bound microbubbles.  An intermittent imaging at a pulsing interval of 10 sec is 
performed to derive the signal only from any remaining freely circulating microbubbles.  The 
image acquired before the destruction pulse corresponds to the signal given from freely 
circulating as well as adherent microbubbles.  The image acquired after the destruction pulse 
corresponds to the signal coming from circulating microbubbles returning to the region of 
interest.  The second image is subtracted from the original one to obtain the signal given only 
from the retained microbubbles at the target site.  The entire imaging procedure typically lasts 
about 30 min, then data analysis is performed offline (Mancini, Greco et al. 2009). 
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Figure 1.8. Commonly used imaging strategy for targeted contrast agent detection in molecular 
imaging.  After a bolus injection, the total contrast signal in tissue rises rapidly and is largely 
attributed to the freely circulating microbubbles (A).  The rate of targeted agent adhesion in 
diseased tissue is highest when the free contrast concentration is high (B).  After a waiting period 
for clearance of freely circulating agents, remaining contrast in tissue is due to retention of targeted 
agents, and imaging of targeted microbubbles is performed.  Taken from Lindner et al. (Lindner 
2004). 
 
Targeted ultrasound molecular imaging offers a powerful tool for physicians to study 
diseases at the molecular and cellular levels, allowing the establishment of a more accurate 
diagnosis, the monitoring of prognosis longitudinally and the tailoring of therapeutic treatments 
for individual patients.  It allows diagnosis and evaluation of the response to a particular therapy 
by quantifying the change in the expression profile of endothelial biomarkers over time.  In a 
clinical scenario, before a therapy (e.g., angiogenic inhibitor) is given, the patient would be 
sequentially administrated a panel of labeled microbubbles, which target a variety of known 
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biomarkers such as integrin αvβ3 (Willmann, Kimura et al. 2010), vascular endothelial growth 
factor receptor 2 (VEGFR2) (Willmann, Lutz et al. 2008) and Notch receptors (Wu, Cain-Hom 
et al. 2010).  This provides a baseline expression for these molecules involved in tumor 
angiogenesis.  When the patient returns after treatment, this same panel could be repeated to look 
for changes in the endothelial expression and regression of the tumor.  Since tumor growth is a 
multiparametric and dynamic process, it is important to repeat this protocol throughout the 
patient’s therapy at various time points in order to assess the progression of the disease and to 
adjust the treatment for more personalized medicine. 
It is important to differentiate targeted molecular imaging from targeted drug delivery.  
Targeted drug delivery requires high specificity between the targeting vehicle and the targeted 
site in order to accurately deliver the therapeutic agent only to the diseased cells.  The concept 
behind drug targeting is to increase the therapeutic index by increasing the potency of the drug 
by delivering a greater dose to the culprit cells and decreasing the toxic side effects by avoiding 
healthy cells.  Targeted drug delivery is therefore extremely challenging.  On the other hand, 
targeted molecular imaging has more relaxed restrictions for targeting specificity since it does 
not require the biomarkers to be expressed only in the targeting organ.  There are fewer concerns 
for toxicity in targeted molecular imaging than in drug delivery because the contrast agent is not 
highly bioactive.  Targeted molecular imaging is a method that gives physicians the tool to assess 
the expression of endothelial biomarkers in order to establish a more accurate diagnosis, to 
monitor the progression longitudinally and to tailor the treatment for individual patients.  It does 
not offer a treatment of the disease, but rather a tool to assess and evaluate the efficacy of the 
treatment. 
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However, current technique still has its limitations and needs further advanced research 
from multiple disciplinarities for the utilization of targeted molecular imaging for clinical 
development.  First, it requires improved knowledge of molecular biology to identify specific 
ligand-receptor pairs that can be used as biomarkers for particular diseases.  This is especially 
important for the development of antiangiogenic therapies in oncology (Sessa, Guibal et al. 
2008).  Second, targeted ultrasound molecular imaging only offers insights to the endothelial 
expression of biomarkers.  The relevancy of their expression to the response rate of a particular 
therapy needs to be pre-established in order to correctly assess the development of the diseases 
and to adjust the treatment for personalized therapy.  Third, targeted ultrasound molecular 
imaging is limited to the vasculature.  Because of the size of the contrast agents, they are 
confined to the blood pool and can only bind to receptors located in the intravascular space, on 
the luminal surface of vascular endothelium.  Intracellular molecular imaging using targeted 
microbubbles is still hard to achieve although phagocytosed microbubble imaging has been 
reported by several groups (Walzog, Schuppan et al. 1995; Villanueva, Jankowski et al. 1997). 
 
1.4.2. Applications for Targeted Microbubbles Used as Molecular Imaging Agents 
1.4.2.1. Angiogenesis 
 Angiogenesis refers to the process of growing new vasculature from pre-existing blood 
vessels and/or circulating endothelial stem cells (Mancini, Greco et al. 2009; Deshpande, Pysz et 
al. 2010).  It is a fundamental biological mechanism that is involved in many physiological 
processes, from wound repair and the female menstrual cycle to the growth and metastasis of 
solid tumors.  Tumor-associated angiogenesis typically has two phases: an avascular and a 
37 
 
 
vascular phase that are separated by the “angiogenic switch” (Deshpande, Pysz et al. 2010).  The 
avascular phase of tumors refers to small lesions that stay dormant for prolonged periods and 
subsist on diffusion of nutrients from the normal host vessels.  These small avascular tumors can 
only grow several millimeters in size before their supply of nutrients becomes limited.  At this 
point, a small subset of dormant tumors enter the vascular phase in which exponential tumor 
growth ensues by shifting the local equilibrium between negative and positive endogenous 
regulators of angiogenesis.  The final result is the alignment and organization of endothelial cells 
to form new blood vessels and a vascular network within the tumor (Mancini, Greco et al. 2009; 
Deshpande, Pysz et al. 2010). 
 Since the shedding of large numbers of tumor cells from the primary tumor may not 
begin until the tumor has developed a sufficient network of blood vessels, angiogenesis may also 
be used to correlate with metastatic potential (Mancini, Greco et al. 2009).  Advances in 
knowledge of tumor angiogenesis have resulted in the identification of several molecules 
involved in tumor angiogenesis signaling, including integrin αvβ3, vascular endothelial growth 
factor receptor 2 (VEGFR2), and notch receptor.  These molecules have been exploited for their 
use as targets for molecular imaging and quantification of tumor angiogenesis at the molecular 
level.  Several groups have shown that targeted microbubbles with monoclonal antibodies 
against vascular endothelial growth factor receptor 2 (VEGRF2) attached to the surface via a 
streptavidin-biotin linker resulted high ultrasound signal in tumor tissue in comparison to non-
targeted control microbubbles (Lyshchik, Fleischer et al. 2007; Rychak, Graba et al. 2007; Lee, 
Lyshchik et al. 2008).  Small peptide sequences are also being studied for their potential as 
targeting ligands for molecular imaging.  Willmann et al. (Willmann, Kimura et al. 2010) 
showed that αvβ3 integrin-targeted microbubbles with surface-conjugated small knottin peptides 
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as the targeting ligand resulted in an imaging signal higher than that provided by large antibody 
labeled microbubbles.  A new approach to increase microbubble-enhanced ultrasound imaging 
signal for detection of tumor angiogenesis was recently explored using dual-targeted 
microbubbles (Deshpande, Pysz et al. 2010).  Both VEGRF2 and integrin αvβ3 targeted ligands 
were attached to the contrast agents for site specific imaging.  Increased signal level was detected, 
and this could be used in cases such as the early detection of cancer when tumors are too small to 
cause detectable morphologic changes but large enough to induce tumor angiogenesis (Willmann, 
Lutz et al. 2008). 
 
1.4.2.2. Inflammation 
 Most of the early development of targeted ultrasound contrast agents has focused on 
imaging inflammation because of its importance in tissue damage and organ dysfunction in many 
disease processes (Mancini, Greco et al. 2009).  Inflammation is mediated by a variety of 
receptors that are exposed to the blood pool.  These molecular biomarkers are well characterized 
and very specific for the regions of inflammation.  Taking these technical factors into 
consideration, the detection of inflammation is ideal for targeted ultrasound molecular imaging. 
 Tissue inflammation is originally assessed through passive targeting using non-targeted 
microbubbles (Villanueva, Jankowski et al. 1997).  These microbubbles bind to the activated 
leukocytes within the microcirculation of the inflamed tissue, and the binding is influenced by 
the composition of the microbubble shell: albumin microbubbles adhesion is mainly through the 
leukocyte β2 integrin Mac-1; while lipid microbubbles adhesion is mainly through opsonization 
by serum complement (Lindner, Dayton et al. 2000).  In vitro studies showed that microbubbles 
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were phagocytosed intact by activated leukocytes within minutes and remained acoustically 
active (Lindner, Dayton et al. 2000; Lindner 2009; Mancini, Greco et al. 2009).  However, the 
ultrasound signal is relatively low because of the small portion of retained contrast agents and 
the viscoelastic damping of microbubbles once phagocytosed.  In order to address this issue, 
targeting ligands are attached to the microbubbles to enhance the avidity of adhesion for 
activated leukocytes.  This active targeting method is more suitable for the detection of mild or 
chronic inflammation using contrast enhanced ultrasound (Lindner 2009).  Monoclonal 
antibodies can be attached to the microbubble surface to target selectins, ICAM-1 and vascular 
cell adhesion molecule-1 (VCAM-1) (Villanueva, Jankowski et al. 1998; Lindner, Song et al. 
2001; Lindner 2009).  Similar to molecular imaging of angiogenesis, the dual-targeting strategy 
is also utilized for inflammation imaging (Ferrante, Pickard et al. 2009).  Under shear flow that 
was similar to physiological conditions, Ferrante et al. showed that dual-targeted microbubbles to 
P-selection and VCAM-1 adhered almost twice as efficiently as single-targeted microbubbles.  
This finding may be useful for the detection of early stage atherosclerosis plaques (Ferrante, 
Pickard et al. 2009). 
 
1.5. Research Motivations and Specific Aims 
 Microbubbles are ubiquitous in nature, and they are important for many industrial 
processes.  Over the past several decades, microbubbles have been developed for biomedical 
applications as ultrasound contrast agents.  More recently, specific ligand molecules are attached 
to the surface of microbubbles in an attempt to combine targeted ultrasound with molecular 
imaging for the detection and monitoring of intravascular pathologies.  In order to improve the 
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circulation persistence time and reduce microbubble-induced complement activation, different 
surface architectures of contrast agents have been proposed, including one with a bimodal PEG 
brush layer.  Prior to this study, there was a need for a better understanding of ligand diffusion 
and conjugation in a bimodal polymer brush layer on the monolayer shell of the microbubbles.  
In addition, more experimental studies, both in vitro and in vivo, were needed in order to provide 
design principles for chemical engineering of the microbubble formulation and to show the 
suitability of this new design for potential clinical applications.  To address these issues, the 
current research project was set to accomplish the following aims: 
1. Characterize ligand diffusion and conjugation in a bimodal PEG brush layer on the 
microbubble shell. 
2. Study microbubble-induced complement activation using microbubbles with different 
surface architectures in vitro. 
3. Study the effect of PEG brush surface architecture on microbubble contrast persistence 
in vivo. 
The following hypotheses were made regarding these specific aims: 
1. Ligand diffusion and binding to the tethered functional groups at the distal end of a 
polymer chain is affected by the PEG overbrush in a bimodal PEG brush layer due to the 
steric hindrance effect.  However, this effect can only be applied to ligands larger than a 
certain size limit since small molecules are expected to diffuse freely through polymer 
brushes. 
2. PEG chains on the surface of microbubbles can efficiently reduce the binding of 
complement proteins to targeted microbubbles, and therefore, reduce their 
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immunogenicity.  This effect is largely influenced by the surface architecture on the 
surface of microbubbles. 
3. Targeted microbubbles with a bimodal PEG brush layer on the surface have longer 
circulation persistence in vivo due to the effective protection from the polymer chains to 
shield the ligands against opsonization, phagocytic uptake and non-specific adhesion. 
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Chapter 2: Ligand Conjugation to Targeted Microbubbles with Bimodal 
Poly(ethylene glycol) Brush Layers 
 
2.1. Introduction 
 As mentioned in the previous chapter, microbubbles are gaining increasing attention from 
the science and engineering communities over the past several decades for being developed as 
ultrasound contrast agents for biomedical applications.  A microbubble is a gas-filled colloidal 
particle with diameter of less than 10 μm, of which the surface typically comprises amphiphilic 
phospholipids self-assembled to form a lipid monolayer shell.  Poly(ethylene glycol) (PEG) 
chains, or PEG chain derivatives, are generally incorporated into the shell of microbubbles as a 
stabilizing emulsifier. 
The same principles of molecular diffusion in a polymer brush that characterize reactions 
in a polymer-grafted flat surface also apply to the surface of a curved gas-liquid interface, such 
as that posed by the surface of a microbubble.  The flexible PEG polymer brush on the 
microbubble surface protects it against coalescence and macromolecule surface adsorption due to 
the steric hindrance effect.  In aqueous solutions, PEG chains assume a coiled configuration 
whose dimensions depend upon polymer chain size and surface density (de Gennes 1980).  Such 
a microstructure exerts a steric pressure and forms a repulsive barrier that inhibits contact-
mediated interactions with the microbubbles (Kenworthy, Hristova et al. 1995; Kim, Klibanov et 
al. 2000).  Large molecules, such as antibodies, are commonly assumed to be excluded from this 
impermeable PEG brush layer.  However, for small molecules, this assumption is not expected to 
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hold because they can find a path to the surface through the excluded volume (Needham, Zhelev 
et al. 1999). 
For molecular imaging applications, the primary goal is to engineer a targeted contrast 
agent that has both high specificity and low immunogenicity.  There are many surface 
functionalization strategies for conjugating targeting ligands to microbubbles, most notably 
through attaching specific ligands to the distal end of tethered PEG chains.  However, targeting 
ligands typically present chemical groups that could trigger an immune response and decrease 
microbubble contrast persistence during circulation.  In order to address this issue, a stealth 
microbubble design with a bimodal PEG brush surface architecture, termed buried-ligand 
architecture (BLA), was proposed by Borden et al. (Borden, Sarantos et al. 2006; Borden, Zhang 
et al. 2008).  The BLA microbubbles involved bimodal PEG polymer chains on the surface; the 
targeting ligand was attached to the shorter PEG chains (~2000 Da) and was hidden, while the 
longer PEG (~5000 Da) overbrush served as a shield to inhibit ligand exposure and, hence, 
reduced the complement activated immune response in addition to prolonging in vivo circulation 
persistence (Figure 2.1C).  BLA microbubbles experienced transient conversion from stealth to 
active under ultrasound radiation force (USRF); the shielded ligand was only revealed for 
binding during microbubble oscillation in the acoustic field but buried again at the end of the 
USRF pulse, allowing triggered and specific adhesion at the targeted site.  This BLA design 
allowed spatial and temporal control of targeted adhesion.  Promising results have shown that 
BLA microbubbles, in comparison with exposed-ligand architecture (ELA) microbubbles, 
reduced immunogenicity without reduction in targeted adhesion. 
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Figure 2.1. Schematic experimental design for ligand conjugation studies.  (A) Molecular structure 
of NHS-FITC showing its estimated dimensions using the well-known Stokes-Einstein equation for 
the diffusion of a sphere in a liquid (Bird, Stewart et al. 2002).  The diffusion constant of a free 
FITC molecule at 21.5 ⁰C in water was calculated to be 0.49x10-9 m2/s (Rani, Pitts et al. 2005), and 
the dynamic viscosity of water was estimated to be 0.979x10-3 kg/m·s.  (B) Schematic diagram of 
streptavidin-FITC showing its estimated dimensions (Cooper, Shen et al. 1994).  (C) Cartoon 
showing the dimensions of a microbubble with either ELA or BLA.  The PEG chain length was 
estimated using self-consistent field (SCF) theory (Lai and Zhulina 1992) using values of 0.44 nm2 
for the average projected area per lipid molecule (Hollinshead, Harvey et al. 2009) and 0.35 nm for 
PEG monomer length.  The lipid monolayer thickness was estimated to be ~3 nm based on the 
persistence length of the stearoyl chains (Borden, Zhang et al. 2008). 
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As mentioned in the previous chapter, post-labeling technique for ligand conjugation to 
the surface of microbubbles offers advantages such as safety, economy and ease-of-use when 
compared with pre-labeling.  In order to utilize post-labeling for BLA microbubbles, one critical 
issue remains to be addressed: will the targeted ligand be able to diffuse through the PEG 
overbrush and bind to the tethered functional groups at the surface?  On one hand, it is  plausible 
that PEG will partially prevent the diffusion and attachment of macromolecules.  However, 
polymer chains in solution are highly dynamic due to thermal fluctuations.  Their thermally 
driven conformational sampling property, the breathing mode of the polymer chains, is expected 
to strongly affect the ligand accessibility.  Jeppesen et al. (Jeppesen, Wong et al. 2001) showed 
that tethered molecules extend well beyond their average equilibrium configuration over an 
experimental time scale of seconds, which broadens the overall spatial range of tethered ligand-
receptor binding.  It opens the argument that, for large molecules that are excluded from the 
brush layer due to steric hindrance, binding to the surface is still possible due to these transient 
excursions of polymer chains.  The kinetics of such reactions will depend on a complex interplay 
between polymer dynamics, molecular diffusion, and intermolecular forces. 
 The purpose of the present study is to experimentally test the differences in ligand 
diffusion and binding rate between various PEG brush architectures on the surface of 
microbubbles, ligand sizes, and binding modes.  ELA and BLA microbubbles were generated to 
represent different polymer architectures. Solute size was varied by using 5/6-carboxyfluorescein 
succinimidyl ester (NHS-FITC) and fluorescein conjugated streptavidin (SA-FITC).  NHS-FITC 
represents a class of smaller molecular ligands (<1 kDa, Figure 2.1A), while SA-FITC represents 
a class of macromolelcular ligands (>10 kDa, Figure 2.1B).  By monitoring the fluorescence 
intensity change during binding, we showed evidence that BLA microbubbles indeed partially 
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prevented the binding of large molecules to the surface while allowing the uninhibited 
attachment of smaller ones.  These findings provide insight for binding of solutes to tethered 
groups in various brush architectures on a Langmuir-monolayer-coated colloidal particle, such as 
the one posed on a microbubble. 
 
2.2. Materials and Methods 
2.2.1. Microbubble Surface Architecture Design 
 The microbubble phospholipid shell used for this study was designed so that the desired 
vertical segregation was achieved to shield the ligand from the surrounding environment when 
the microbubble was static, and only to reveal the ligand for targeting when the microbubble was 
oscillating in an ultrasound field (Figure X) (Borden, Zhang et al. 2008).  The analytical 
expressions used for calculating the PEG brush heights were derived from self-consistent field 
theory by Birshtein et al. (Birshtein, Liatskaya et al. 1990), and are as follows: 
𝐻0 = �8𝑝𝑣𝜎𝜋2 �1/3 𝑁𝑆  Equation 2.1 
𝐻𝑆 = 𝐻0�1 − 𝑞2/3  Equation 2.2 
𝐻𝐿 = 𝐻0�1 + 𝛼𝑞1/3�  Equation 2.3 
where 𝐻0, 𝐻𝑆 and 𝐻𝐿 are the monodisperse, short and long chain brush heights, respectively; 𝑝 is 
the chain stretching parameter (assumed unity for the flexible PEG chains); 𝑣 is the second virial 
coefficient (assumed unity for PEG in water at standard temperature and pressure); 𝜎  is the 
normalized surface coverage; 𝑁𝑆 is the persistence length of the short chain; 𝑞 is the fraction of 
the long chain and 𝛼 is the relative difference in chain lengths.  The value predicted using these 
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expressions are the PEG brush heights as time and spatial averages, and are expected to have 
local variations due to polymer thermal fluctuations (Jeppesen, Wong et al. 2001) and monolayer 
shell heterogeneities (Borden, Pu et al. 2004; Borden, Martinez et al. 2006).  Equally importantly, 
the above expression does not include the attractive intermolecular interactions between PEG 
chains (such as hydrogen bond formation (Israelachvili 1991)) or the additional mass effect of 
the conjugated RGD peptide on the distal end of the PEG chains. 
 
2.2.2. Materials 
All phospholipids were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL), 
including 1,2-distearyol-sn-glycero-3-phosphocholine (DSPC), 1,2-distearyol-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (DSPE-PEG2000), 1,2-distearyol-
sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)2000] (DSPE-PEG2000-A), 
1,2-distearyol-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene glycol)2000] 
(DSPE-PEG2000-B) and 1,2-distearyol-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)5000] (DSPE-PEG5000).  The emulsifier polyoxyethylene-40 
stearate (PEG40S) was purchased from Sigma-Aldrich (St. Louis, MO).  All microbubble shell 
components were dissolved in chloroform (Sigma-Aldrich) and stored in the freezer at -20 ⁰C.  
The perfluorobutane gas (PFB, 99 wt% purity) used for microbubble generation was purchased 
from FluoroMed, L.P. (Round Rock, TX).  The fluorophore probes 3,3’-
dioctadecyloxacarbocyanine perchlorate (DiO) and 1,1’-dioctadecyl-3,3,3;3;-
tetramethylindocarbocyanine perchlorate (DiI) solutions (Invitrogen; Eugene, OR) were used to 
label microbubbles during the size-isolation and multimodality experiments, respectively.  NHS-
FITC and SA-FITC were obtained from Pierce (Rockford, IL) and dissolved in N,N-
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dimethylformamide (DMF; Sigma-Aldrich) and 18 MΩ-cm deionized water (Direct-Q Millipore; 
Billerica, MA), respectively.  Both solutions were stored at 4 ⁰C and discarded after 2 weeks. 
 
2.2.3. Microbubble Generation 
The compositions of microbubble samples for each experiment performed are listed in 
Table 2.1.  The indicated amount of each lipid species was mixed in a separate vial, and 
chloroform was evaporated by flowing a steady stream of nitrogen over the vial during vortexing 
for about 10 minutes followed by several hours under house vacuum.  0.01 M phosphate buffer 
saline (PBS) solution (Sigma-Aldrich) was filtered using 0.2 μm pore size polycarbonate filters 
(VWR; West Chester, PA), and mixed with 10 vol% glycerol solution (Sigma-Aldrich) and 10 
vol% 2-propanol solution (Sigma-Aldrich) to increase viscosity and lipid solubility.  The dried 
lipid film was then hydrated with PBS mixture to a final lipid/surfactant concentration of 1 
mg/mL. 
 
Table 2.1. Microbubble compositions for ligand conjugation studies 
Experiment 
Phospholipid Composition (mol%) 
DSPC DSPE-PEG2000 DSPE-PEG2000-A DSPE-PEG2000-B DSPE-PEG5000 
ELA Control 90 10 - - - 
ELA-Biotin 90 8 - 2 - 
ELA-Amine 90 8 2 - - 
BLA Control 90 2 - - 8 
BLA-Biotin 90 - - 2 8 
BLA-Amine 90 - 2 - 8 
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Two methods of microbubble generation were used.  For size isolation experiments, 
probe sonication was used as described elsewhere (Feshitan, Chen et al. 2009).  Briefly, the 
hydrated lipid mixture was first sonicated with a 20 kHz probe (Model 250A, Branson 
Ultrasonics, Danbury, CT) at low power (power setting dialed to 3/10; 3 W) in order to heat the 
lipid suspension above the DSPC main phase transition temperature (~ 55 °C) and further 
disperse the lipid aggregates into small, unilamellar liposomes (Kim and Franses 2005).  1 mM 
DiO solution was added to the lipid suspension at an amount of 1 μL DiO solution per mL of 
lipid mixture.  PFB was introduced by flowing it over the surface of the lipid suspension.  
Subsequently, high power sonication (power setting dialed to 10/10; 33 W) was applied to the 
suspension for about 10 s at the gas-liquid interface to generate microbubbles.  No extra washing 
steps were done for the size-isolation experiment.  For the multimodality and FITC-ligand 
binding experiment, the shaking method was used to generate microbubbles.  The lipid 
suspension was first heated to 60 °C in a digital heatblock (VWR) for 10 min, and then sonicated 
at 60 °C in a bath sonicator (Model 1510, Branson Ultrasonics; Danbury, CT) for 30 s so that the 
lipid aggregates were completely dispersed.  1 mM DiI solution was added to the lipid 
suspension at an amount of 1 μL DiI solution per mL of lipid mixture to generate fluorescently 
labeled microbubbles for the multimodality experiment.  2 mL of lipid suspension was then 
transferred to a 3 mL serum vial and sealed for gas exchange.  Gas exchange of the vial 
headspace was done by first vacuuming out air and then flowing PFB into the vial.  At least three 
cycles of gas exchange were done to ensure the lipid suspension was saturated with PFB, and 
subsequently a 27G needle was used to vent the vial in order to release the excess pressure.  
Microbubbles were formed by shaking with a VialMix (ImaRx Therapeutics; Tucson, AZ) for 45 
s.  The generated microbubbles were then diluted to 10 mL suspension with PBS, and washed 3 
50 
 
times by centrifugation flotation in a bucket-rotor centrifuge (Model 5804, Eppendorf; Westbury, 
NY) at 250G for 5 min.  The microbubble cake was finally diluted with PBS for subsequent 
experiments.  For NHS-FITC binding, pH adjusted PBS solution (pH 8.5) was used.  PBS at 
physiological pH (7.4) was used for all other experiments, unless otherwise stated. 
 
2.2.4. Microbubble Size Isolation and Flow Cytometry Gate Determination 
Microbubble size isolation was done as described elsewhere (Feshitan, Chen et al. 2009).  
This technique allowed us to more effectively isolate microbubbles with a desired diameter due 
to their multimodal size distribution.  Three microbubble size ranges were isolated: 1-2 μm, 4-5 
μm and 6-8 μm.  An Accusizer optical particle counter (NICOMP Particle Sizing System; Santa 
Barbara, CA) was used to measure the size distribution and particle concentration.  Flow 
cytometry (1x105 events) was performed immediately afterward using an Accuri C6 flow 
cytometer (Accuri Cytometers Inc.; Ann Arbor, MI).  The forward-scatter height (FSC-H) 
threshold was adjusted to delineate the microbubble populations from instrument and sample 
noise.  The system setting was held constant for all subsequent measurements. 
 
2.2.5. Optimization of FITC Ligand:Functionalized Lipid Ratio 
Based on the size distribution and concentration data obtained using the Accusizer, each 
microbubble sample was diluted to about 1x109 #/mL.  It is reported that the average projected 
area per lipid molecule for DSPC is 0.44 nm2 (Hollinshead, Harvey et al. 2009).  Keeping the 
same value for the other PEGylated phospholipid species, the total number of lipid molecules on 
the shell surface was calculated.  Assuming the uptake of lipid molecules to the shell was the 
same for all species, the relative molar ratio of lipid components in the microbubble shell is 
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expected to be the same as in the bulk suspension (Borden, Martinez et al. 2006).  The total 
number of functional groups present on the surface of microbubbles was then calculated, and the 
excess amount of FITC ligand (molar ratio varied from 0.04:1 to 100:1 and 0.05:1 to 1.5:1 for 
NHS-FITC:DSPE-PEG2000-A and SA-FITC:DSPE-PEG2000-B, respectively) needed for 
conjugation was obtained.  500 μL of microbubble suspension was transferred to a 3 mL syringe 
for NHS-FITC binding, and 100 μL of microbubble suspension was transferred to a 1 mL 
syringe for SA-FITC binding.  Samples were incubated with the indicated amount of FITC 
ligand in the dark overnight on a benchtop rotator at room temperature.  Unreacted NHS-FITC or 
SA-FITC was removed by centrifuging the sample at 250G for 5 min.  The concentrated 
microbubble cake was then re-suspended in PBS and analyzed by flow cytometry. 
 
2.2.6. FITC Ligand Binding Kinetics 
Microbubble suspensions were incubated with the indicated amount of FITC ligand in the 
dark on a benchtop rotator at room temperature.  FITC ligand binding was continuously 
monitored for 6 hrs.  2 μL samples were taken out at different time points for flow cytometry 
measurement.  A pseudo-first order association kinetics model (Saltzman 2001), given by 
Equation 2.4, was used to fit all median fluorescence intensity versus time data, 
𝑌 = 𝑌𝑚𝑎𝑥(1 − 𝑒−𝑘𝑜𝑏𝑠𝑡) Equation 2.4 
where Ymax is maximum median fluorescence intensity (MFI) increase and kobs is the observed 
binding rate constant in units of hr-1.  Curve fitting parameters for each data set were obtained 
using the nonlinear regression tool in Prism software (GraphPad Software, Inc; La Jolla, CA).  
All curves showed reasonable goodness of fit with R2 values approximately 0.92 and above, 
except for SA-FITC ELA 1-2 μm microbubble sample (discussed below). 
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2.2.7. Optical Microscopy 
Direct visual confirmation of microbubble fluorescence was performed within 24 hrs 
after FITC ligand binding.  Microbubble samples were taken out of the reaction syringe and 
imaged at room temperature.  Still images were taken using an Olympus 1X71 inverted 
microscope (Olympus; Center Valley, PA), and Z-scan images were taken using an Olympus 
BX60M upright microscope with 0.5-μm scan step size across a 10-μm distance.  Images were 
captured in epi-fluorescence mode using a high-resolution digital camera (Orca HR, Hamamatsu; 
Japan) with a 100x oil immersion objective and processed with Simple PCI software (C-Imaging; 
Cranberry Township, PA).  Subsequent image analysis was done using ImageJ 1.4g software 
(NIH; Washington DC.). 
 
2.3. Results and Discussion 
2.3.1. Microbubble Size Isolation and Flow Cytometry Gate Determination 
Our group recently introduced a microbubble size isolation technique using differential 
centrifugation (Feshitan, Chen et al. 2009).  It provides a rapid and robust method for size 
selection and reduces polydispersity of microbubble samples.  As we previously reported, it also 
isolated the microbubbles from precursor liposomes and non-echogenic nanobubbles, which may 
be recycled for additional microbubble production.  Based on the size distribution, we estimated 
that only between 1 – 10% of the original lipid molecules were incorporated into the 
microbubble shells.  Similar to our previous report (Feshitan, Chen et al. 2009), we observed a 
multimodal size distribution using both the Accusizer and the flow cytometer.  The black 
symbols shown in Figure 2A and 2B are the number % and volume % of sizing data from a 
freshly made (polydisperse) sample.  Distinct peaks in both plots were detected, especially in the 
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volume % distribution, indicating dominant size ranges in the microbubble population.  These 
distinct peaks were consistent across all microbubble samples.  The corresponding forward- 
versus side-scatter (FSC vs. SSC) density plot for the polydisperse sample is shown in Figure 2C.  
A characteristic serpentine shape was detected as previously observed by our group (Feshitan, 
Chen et al. 2009).  The serpentine scattergram appeared to correlate with the distinct peaks 
shown in the size distribution determined by Accusizer. 
In order to further investigate microbubble size multimodality, we used a fluorescence-
based detection method.  DiI labeled microbubbles were centrifuged to remove the liposomes, 
nanobubbles and some of the 1-2 μm population so that the 1-2 μm and 4-5 μm peaks shown in 
the number % size distribution were of similar magnitude (Figure 2.3A).  This step was 
necessary since 1-2 μm microbubbles present in a freshly made suspension dominated the events 
detected using flow cytometry.  Microbubbles with different sizes could not be otherwise 
detected and represented on the fluorescence histogram.  The FSC vs. SSC density plot and 
median fluorescence intensity (MFI) histogram of the centrifuged sample is shown in Figure 
2.3B and 2.3C.  The MFI histogram clearly showed a multimodal distribution that corresponded 
to the Accusizer measurement, lending support to the validity of the multimodal size distribution 
rather than an optical scattering phenomenon. 
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Figure 2.2. Microbubble size isolation and flow cytometry gate determination.  Number-weighted 
(A) and volume-weighted (B) microbubble size distributions before and after size isolation are 
compared.  Each curve is the average of three measurements with its SD plotted as error bars.  (C) 
Forward-scattering (FSC) versus side-scattering (SSC) plots of corresponding microbubble samples 
before and after size isolation.  A tight fitted P gate and a rectangular R gate were drawn for each 
scatter plot and saved as templates for all subsequent measurements in order to identify each size 
subpopulation in a polydisperse suspension. 
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Figure 2.2A and 2.2B also show the sizing data for the size-isolated microbubbles with 
diameter between 1-2 μm, 4-5 μm and 6-8 μm.  The volume-weighted median diameters ± 
standard deviations (SD) were 1.71±0.01 μm, 4.07±0.12 μm and 7.13±0.12 μm, respectively.  
The corresponding FSC vs. SSC density plots for each population are shown in Figure 2.2C.  A 
tight-fitted (P) gate and a rectangular (R) gate was drawn around the densest region of the scatter 
plots to identify each size subpopulation.  The density plots for 4-5 μm and 6-8 μm size-isolated 
samples showed faint traces of the serpentine shape similar to the polydisperse sample, which 
might result from the presence of residual smaller microbubbles in the sample. By combining 
differential centrifugation and flow cytometric gating, we were able to accurately identify 
microbubble subpopulations in a polydisperse sample.  The gate information determined using 
the size-isolated samples was saved as a template for all subsequent analyses of polydisperse 
microbubble suspensions.  In order to ensure a proper representation of the entire microbubble 
population, 1x105 events were measured for all samples. 
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Figure 2.3. Illustration of multimodal size distribution of fluorescently labeled microbubbles.  (A) 
Size distribution of the DiI labeled microbubble suspension after partially removing part of the 1-2 
μm population.  The 1-2 μm and 4-5 μm peaks shown in the number% size distribution were of 
similar magnitude to ensure proper event detection using flow cytometry.  (B) FSC versus SSC 
density plot of the same microbubble suspension.  (C) MFI histogram of the same microbubble 
suspension showing a multimodal size distribution that corresponded to the Accusizer 
measurement. 
 
2.3.2. Optimization of FITC Ligand:Functionalized Lipid Ratio 
 Flow cytometry was used to analyze the binding of the FITC ligands to the PEG-terminal 
functional groups.  Figure 2.4 shows sample MFI histograms before and after ligand conjugation.  
The washed polydisperse suspension, which had a dominant 1-2 μm peak and sometimes a 
relatively large 4-5 μm peak, gave a log-normal or sometimes bimodal distribution in 
fluorescence intensity (e.g., Figure 2.4A).  Increased MFI, which was indicated by a shift of the 
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distribution to the right, confirmed the binding of FITC ligand on the microbubble surface.  
Control microbubbles showed very little or no MFI increase for either NHS-FITC or SA-FITC, 
regardless of the microbubble surface architecture. 
 
 
Figure 2.4. Typical flow cytometry fluorescence intensity histograms of microbubbles with different 
architectures before and after ligand conjugation.  (A) NHS-FITC ELA binding.  (B) SA-FITC 
ELA binding.  (C) NHS-FITC BLA binding.  (D) SA-FITC BLA binding. 
 
 In order to perform a sensitive analysis of ligand conjugation kinetics, studies were done 
to find the saturation point for NHS-FITC and SA-FITC (Figure 2.5).  For both ELA and BLA, 
MFI change increased by about 3 orders of magnitude when the NHS-FITC:DSPE-PEG2000-A 
molar ratio was increased from 0.04 to 20 and leveled off to 100 (Figure 2.5A).  A similar trend 
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was observed for SA-FITC:DSPE-PEG2000-B, although the saturation molar ratio occurred at 
0.5 (Figure 2.5B).  The 0.5 saturation molar ratio was consistent with the theoretical prediction 
since each SA-FITC molecule has four biotin binding pockets with only two facing the PEG 
brushes at a time.  Both molar ratios were identified as the saturation point and used to calculate 
the appropriate amount of FITC ligand for all subsequent kinetics experiments. 
 
 
Figure 2.5. Optimization of ligand:functionalized lipid ratio.  MFI was measured before and after 
microbubble samples reacted with various amounts of ligands after 12 hr at room temperature.  (A) 
NHS-FITC/DSPE-PEG2000-A with molar ratio varied between 0.04 and 100.  A molar ratio of 20 
(dashed line) was used for all subsequent kinetics studies.  (B) SA-FITC/DSPE-PEG2000-B with 
molar ratio varied between 0.01 and 1.5.  A molar ratio of 0.5 (dashed line) was used for all 
subsequent kinetics studies. 
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2.3.3. Small Molecule (NHS-FITC) Binding Kinetics 
 It is commonly accepted that the protective mechanism of PEG polymer chains for 
liposomes (Klibanov, Maruyama et al. 1990) or microbubbles (Klibanov 1999) comes from their 
flexibility to form a “cloud” that sterically hinders the adsorption of opsonins to the surface and 
hence reduces the rapid clearance of these colloidal particles by the MPS (Torchilin, Papisov et 
al. 1995).  However, it is unclear whether this mechanism interferes with the diffusion and 
attachment of targeting ligands to the buried PEG chains.  It was hypothesized that smaller 
molecules, such as NHS-FITC, would be able to diffuse freely through the excluded volume of 
PEG and bind to the tethered amino groups at the end of the shorter PEG chains for both 
microbubble surface architectures.  Indeed, by monitoring MFI increase using flow cytometry, 
almost identical NHS-FITC binding kinetics for each size range were obtained between ELA and 
BLA over 6 hr (Figure 2.6).  Table 2.2 summarizes the best-fit values obtained for the pseudo-
first-order kinetics parameter.  Ymax and kobs values for BLA microbubbles were more than 80% 
of those measured for ELA, independent of microbubble size.  This result confirmed the 
hypothesis that the diffusion and binding of NHS-FITC to the tethered amino groups was not 
significantly inhibited by the PEG overbrush. 
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Figure 2.6. NHS-FITC binding kinetics to the tethered amino functional groups after microbubble 
formation.  MFI was monitored continuously over 6 hr, and MFI change before and after reaction 
for each size range was plotted at different time points.  Data was fitted using a pseudo-first-order 
reaction kinetic model.  ELA and BLA showed good agreement for both the observed binding rate 
and the final MFI over the experimental time scale. 
 
 
Table 2.2. Summary of best-fit values obtained for NHS-FITC ligand binding kinetics curves using a 
pseudo-first-order kinetics equation (Eq 1) 
 
NHS-FITC Binding 
 
ELA 
 
BLA 
Sample Size Range Ymax (AFU)* kobs (hr-1) 
 
Ymax (AFU)* kobs (hr-1) 
1-2 μm 1.1 x 104 0.67  9.6 x 10
3 0.65 
4-5 μm 7.5 x 104 0.66  6.0 x 10
4 0.64 
6-8 μm 1.9 x 105 0.64  1.7 x 10
5 0.58 
* AFU: arbitrary fluorescence unit 
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Figure 2.7. SA-FITC binding kinetics to the tethered biotin functional groups after microbubble 
formation.  ELA reached saturation binding within the first 10 min of reaction.  However, BLA 
showed a gradual increase of MFI over the first 2 hr of reaction with a half-time around 30 min for 
all size ranges.  The differences in binding rate agrees with the hypothesis that the PEG overbrush 
interferes with the diffusion of large molecules to the surface of microbubbles and partially blocks 
their binding to the buried functional end groups. 
 
In order to further analyze the binding kinetics, MFI changes were normalized using the 
final MFI value taken at 6 hr (Figure 2.8A and 2.8C).  Interestingly, binding curves for all three 
size ranges collapsed to a single curve over the 6 hr experiment.  This indicated that NHS-FITC 
ligand binding occurred at the same rate, independent of microbubble size, in both ELA and 
BLA designs. 
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Figure 2.8. Comparison of normalized MFI change between ELA and BLA microbubbles for all 
size ranges.  The last measured MFI was used for normalization as the final saturation value.  The 
curves were obtained using a pseudo-first-order kinetic model.  The fitted binding rate for all size 
ranges was the same for each condition, indicating that the ligand binding rate was independent of 
microbubble size. 
 
 NHS-FITC is similar in molecular weight to several small-molecule peptide ligands, such 
as cyclic-arginine-glycine-asparagine (RGD).  RGD has been shown to bind to an overexpressed 
angiogenic biomarker, αvβ3 integrin, with high affinity and specificity (Miller, Pien et al. 2005; 
D'Andrea, Del Gatto et al. 2006).  Using RGD labeled microbubbles with ultrasound molecular 
imaging, one can monitor and guide therapy of VEGF-blockage for cancer therapy (Iagaru, Chen 
et al. 2007; Hargreaves 2008).  By showing that NHS-FITC was able to diffuse through the PEG 
overbrush and bind to the tethered PEG, the feasibility of post-labeling for small-molecule ligand 
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(<1 kDa) to BLA microbubbles to generate stealth targeted ultrasound contrast agent was 
demonstrated. 
 
2.3.4. Macromolecule (SA-FITC) Binding Kinetics 
 It was hypothesized that macromolecules (>10 kDa), such as SA-FITC, would not be able 
to diffuse freely through the PEG overbrush and bind to tethered biotin end groups due to steric 
hindrance in the buried-ligand architecture.  Indeed, Figure 2.7 shows significant differences in 
SA-FITC binding curves between ELA and BLA for each microbubble size range.  ELA binding 
curves reached the saturation MFI values within the first 10 min of reaction and stayed constant 
throughout the rest of the experiment.  BLA binding curves, on the other hand, showed a gradual 
increase during the first hour of reaction, reaching the saturation MFI values at approximately 2 
hr.  the final MFI values for each size range in ELA were significantly higher than those in BLA, 
with the average Ymax percentage being only 58% of that for ELA (Table 2.3), indicating that the 
binding of SA-FITC to buried biotin groups was significantly inhibited by the longer PEG chains. 
 
 
Table 2.3. Summary of best-fit values obtained for SA-FITC ligand binding kinetics curves using a 
pseudo-first-order kinetics equation (Eq 1) 
 
SA-FITC Binding 
 
ELA 
 
BLA 
Sample Size Range Ymax (AFU)* kobs (hr-1) 
 
Ymax (AFU)* kobs (hr-1) 
1-2 μm 6.3 x 103 -  4.8 x 10
3 1.80 
4-5 μm 7.7 x 104 -  4.- x 10
4 2.18 
6-8 μm 2.5 x 105 -   1.1 x 105 1.98 
* AFU: arbitrary fluorescence unit 
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 Again, the effect of microbubble size on SA-FITC conjugation was investigated.  
Normalized MFI changes showed all binding rates collapsed into a single curve, indicating that 
SA-FITC binding for microbubbles with different diameters was the same (Figure 2.8B and 
2.8D).  Similar to the case of NHS-FITC, the diffusion and binding of SA-FITC was not affected 
by microbubble size for either ELA or BLA designs. 
 The kinetics curves for the 1-2 μm size range are shown in Figure 2.9 to further illustrate 
the significant difference in binding rate between ELA and BLA microbubbles for different 
ligand sizes. For NHS-FITC, the normalized binding curves showed very little difference 
between the two brush architectures over 6 hr, with the fitted kobs values in close agreement 
between ELA and BLA (Table 2.4).  On the other hand, for SA-FITC binding, the ELA kinetic 
curve closely resembles a step function with the MFI value reaching its saturation Ymax within 10 
min; yet the BLA kinetic curve showed a more gradual increase over time with a much slower 
binding rate constant.  Unfortunately, due to the fact that ELA samples reached their saturation 
MFI before the first flow cytometry measurement was taken, reliable kobs values were not 
obtained for a more quantitative comparison. 
 
Table 2.4. Summary of best-fit values obtained for normalized FITC ligand binding kinetics curves* 
 
NHS-FITC Binding 
 
SA-FITC Binding 
Sample Size Range ELA kobs (hr-1) BLA kobs (hr-1) 
 
ELA kobs (hr-1) BLA kobs (hr-1) 
1-2 μm 0.63 0.64  - 1.40 
4-5 μm 0.62 0.63  - 1.58 
6-8 μm 0.61 0.59   - 1.48 
*All MFI values were normalized by the corresponding best-fit Ymax values listed in Table 2.2 and 2.3 
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Figure 2.9. Sample comparison between normalized MFI change for ELA and BLA 1-2 μm 
microbubbles.  The binding rate for NHS-FITC between ELA and BLA was the same, confirming 
the hypothesis that the diffusion and attachment of small molecules to the tethered short PEG 
chains was not affected by the overbrush.  On the other hand, the binding rate for SA-FITC 
between ELA and BLA was significantly different, particularly during the first 30 min of reaction, 
indicating that the binding of large SA-FITC molecules was slowed by the PEG overbrush in BLA. 
 
2.3.5. Availability of Tethered Functional Groups in a Bimodal Polymer Brush 
 Interestingly, the PEG overbrush did not completely eliminate macromolecule 
conjugation.  Previous findings have shown that phase separation between phospholipid species 
can exist on lipid monolayers coating the microbubble surface (Kim, Costello et al. 2003; Borden, 
Pu et al. 2004; Borden, Martinez et al. 2006; Tanwir and Tsoukanova 2008; Lozano and Longo 
2009; Lozano and Longo 2009).  It is suggested here that two distributions of PEG-lipid 
conjugates may exist on the surface of microbubbles, which are formed during the initial self-
assembly process: domains with DSPE-PEG2000-X and DSPE-PEG5000 well mixed, and 
peripheral regions comprising buried ligands that are not completely shielded by the PEG 
overbrush (Figure 2.10).  Smaller ligands, such as NHS-FITC, may diffuse freely through the 
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excluded volume of PEG and bind to the amino groups in the center of the PEG-rich domains.  
Needham and co-workers (Needham, Zhelev et al. 1999; Kim, Klibanov et al. 2000) modeled the 
diffusion of small molecules through a surface-grafted PEG layer as a function of polymer 
molecular weight.  It was found that as the PEG molecular weight increased the volume fraction 
of polymer in the excluded volume decreased, indicating that there was more free-water volume 
for small molecules to penetrate.  The results obtained in the present study illustrated that the 
presence of the DSPE-PEG5000 overbrush does not interfere with the diffusion of NHS-FITC 
molecules to the tethered amino groups. 
 On the other hand, the binding of SA-FITC to tethered biotin groups in BLA 
microbubbles was significantly lower (~58%) than that for ELA microbubbles.  It is proposed 
that this is because the observed binding of SA-FITC mainly occurred to the tethered biotin 
groups on the peripheral DSPE-PEG2000-B chains, where the longer DSPE-PEG5000 chains did 
not form a complete dense cloud over the buried biotin groups.  In the central PEG-rich domain 
regions, SA-FITC molecules could not overcome the steric hindrances of DSPE-PEG5000 chains 
and therefore were physically inhibited from binding to the biotin groups, which resulted in the 
differences in the final saturated MFI values between ELA and BLA microbubbles. 
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Figure 2.10. Cartoon illustrating possible phase separation between lipid species on the surface of 
microbubbles. 
 
 It is also possible that the transient excursion of PEG chains could result in some SA-
FITC:DSPE-PEG2000-B binding in the central regions of the domains.  If this were the case, 
SA-FITC would continue to bind, and a linear increase of MFI over time would be observed.  
However, the significantly lower MFI values of BLA microbubbles and the nonlinear binding 
curves both indicated that such events occurred at a very low frequency over the experimental 
period, suggesting that physical inhibition of SA-FITC molecules due to the steric repulsion 
resulted the difference in final MFI values between ELA and BLA microbubbles. 
 Using a surface force apparatus, Moore and Kuhl (Moore and Kuhl 2006) measured the 
specific and nonspecific forces between a streptavidin-coated surface and a bimodal PEG 
mushroom with buried biotin and a similar lipid composition as what was tested in the present 
study.  It was found that the presence of longer PEG did not significantly change the capture 
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distance of specific adhesion even though the steric repulsion between these two surfaces was 
increased.  The discrepancy between their results and what is reported here can be explained by 
the differences in experimental design.  Moore and Kuhl had two surfaces slowly approach each 
other, allowing the tethered biotin end groups enough time to equilibrate and bind to apposed 
streptavidin molecules under compression (Moore, Mulder et al. 2008).  The present study is 
different in that microbubbles and ligand molecules diffused freely in solution.  There were no 
external forces acting on the system.  Therefore, all measured binding events were the result of 
passive diffusion.  The results presented here confirmed the previous findings reported by 
Borden et al. (Borden, Sarantos et al. 2006) using a similar system, where microbubbles were 
flowing through a parallel-plate flow chamber and allowed to bind to surface-adsorbed avidin 
molecules.  It was shown that BLA microbubbles were able to successfully bury the targeting 
ligands and reduce specific adhesion in comparison with ELA microbubbles when no USRF was 
applied.  In the current study, the presence of longer PEG showed a significant effect on the 
binding of SA-FITC, supporting the hypothesis that the diffusion of macromolecules through the 
PEG overbrush was partially inhibited. 
 
2.3.6. Streptavidin-Induced Microbubble Surface Structure 
 Epi-fluorescence microscopy images provided direct visual confirmation for the 
conjugation of FITC ligands to the surface of microbubbles (Figure 2.11).  All microbubble 
samples appeared to be stable during observation.  When compared with bright-field images, all 
polydisperse microbubbles were visible under epi-fluorescence mode (data not shown).  There 
was no preferential attachment of ligands due to microbubble size.  Microstructural features 
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within the lipid shells were detected (see arrows in Figure 2.11A and 2.11B), indicating non-
uniform distribution of FITC ligand on the microbubble surface. 
 
 
Figure 2.11. Epi-fluorescence images of microbubble samples after ligand binding.  Arrows point to 
microstructural features of non-uniform FITC labeling.  (A) NHS-FITC labeled ELA microbubbles.  
(B) NHS-FITC labeled BLA microbubbles.  (C) SA-FITC labeled ELA microbubbles.  (D) SA-FITC 
labeled BLA microbubbles.  Scale bars correspond to 10 μm. 
 
 Surprisingly, during the preliminary screening for ligand saturation, it was noticed that 
the number of events (event%) that fell within the tight polydisperse P gate on the FSC versus 
SSC plot detected by flow cytometry stayed relatively constant for all microbubble samples 
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except for SA-FITC/ELA binding (Figure 2.12).  A significant decrease of event% inside the 
gate was repeatedly observed immediately after SA-FITC binding to ELA microbubbles, and the 
relative change stayed constant throughout the 6 hr experiment.  This change of event% was not 
accompanied by a corresponding decrease in total particle concentration (data not shown).  Since 
SSC is a measure of particle granularity and texture (Traganos 1984), it was then hypothesized 
that this change of scattering property resulted from a change of microbubble surface structure. 
 
 
Figure 2.12.  Flow cytometric identification of surface stractures induced by streptavidin binding.  
Shown is in the change in the percentage of events that fell within the serpentine P gate and the 
accompanying FSC versus SSC plots. 
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 Epi-fluorescence images verified this hypothesis.  Figure 2.11B (upper right) shows 
typical SA-FITC labeled ELA microbubbles exhibiting complex surface structure (e.g., folds, 
domains and protrusions) that were not normally found on either SA-FITC labeled BLA 
microbubbles or NHS-FITC labeled ELA microbubbles.  Similar structures were found on 
almost all SA-FITC bound ELA microbubbles that were large enough (diameter >~3 μm) to be 
examined by optical microscopy.  No visible changes, such as collapse, aggregate formation or 
vesicles shedding, were observed for these microbubbles over the observation time period 
(typically around 10-15 min). 
 The streptavidin-induced surface structures (folds and protrusions) were not observed for 
either SA-FITC labeled BLA microbubbles or NHS-FITC labeled ELA microbubbles, and they 
can be correlated to the flow cytometry measurement very closely (Figure 2.12).  Figure 2.13 
shows a cartoon concept of the streptavidin-induced surface structure.  It is speculated that, 
during the early binding period, incomplete surface coverage of biotin moieties by the SA-FITC 
led to cross-linking between the monolayer shell and folds extending into the aqueous phase.  
(Small bilayer folds and protrusions were likely presented as defects in the microbubble shell 
prior to SA-FITC binding.)  Furthermore, the cross-linking led to an effective spreading pressure 
of the bilayer fold over the monolayer surface, which pulled more lipids from the monolayer 
plane into the fold.  As the spreading proceeded, a fold would grow until the SA-FITC molecules, 
which were the limiting reagent, were depleted or the SA-FITC molecules reached their 
maximum surface density.  Fold nucleation and growth would likely be nucleated from shell 
heterogeneities and would induce gas dissolution from the core, consistent with results presented 
in Figure 2.11 and 2.12.  This explanation was inspired by previous work done by others 
showing adhesion between apposing lipid vesicles induced by avidin-biotin interactions (Noppl 
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and Needham 1996; Nam and Santore 2007; Nam and Santore 2007).  The avidin-biotin 
spreading pressure was able to bend and stretch the bilayer membranes to form large contact 
regions (e.g., plaques).  Previous work done by Nam and Santore (Nam and Santore 2007) 
showed that the time scale for spreading in general was on the order of 1 second.  For the present 
experiment, by the time the first data point was taken at 10 min, it is assumed that the growth and 
spreading of the folds and protrusions were completed and the system had reached a new 
equilibrium state. 
 
 
Figure 2.13.  Cartoon illustrating possible streptavidin-induced monolayer protrusions. 
 
 In order to test the hypothesis that the formation of these surface structures was a 
streptavidin-biotin mediated phenomenon rather than a manifestation of gas core dissolution 
owing to dilution, the microbubble concentration change over the 6 hr experiment period was 
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plotted for each size range using the flow cytometry data (Figure 2.14).  For ELA microbubbles 
binding to SA-FITC, all size ranges showed a significant decrease in concentration within the 
first 10 min and stayed constant throughout the rest of the experiment.  For BLA microbubbles, 
on the other hand, none of the size ranges showed a significant change of concentration.  Since 
both samples were prepared and diluted in the same manner, this result eliminated the possibility 
that the observed surface structures resulted simply from microbubble dissolution. 
 
 
Figure 2.14.  Concentration change for ELA and BLA microbubbles upon SA-FITC binding over 6 
hr.  Concentration data were obtained from flow cytometry data using the tight-fitted P gates. 
 
 The absence of the wrinkled structure observed for BLA microbubble could be due to the 
inhibited macromolecule diffusion into the bimodal PEG layer.  The availability of the tethered 
biotin group in a bimodal PEG brush was much lower than that for the ELA counterpart.  If there 
were not enough biotin-streptavidin interactions within a close proximity, the system may not 
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have been able to bend and stretch the monolayer enough to promote the growth of folds and 
protrusions. 
 While Rychak et al. (Rychak, Lindner et al. 2006) showed that they could use mechanical 
pressurization to create wrinkled microbubbles with increased surface area for loading targeting 
ligands and facilitating adhesion, a new method for inducing complex surface structure 
formation that resulted in similar folds and protrusions is presented in this study.  The excess 
area of SA-FITC labeled ELA microbubbles may also stabilize specific adhesion.  However, 
these surface structures may increase immunogenicity.  Regardless, it was shown for the first 
time that these microbubble surface structures may be quantified using flow cytometry. 
 
2.4. Conclusion 
 NHS-FITC and SA-FITC were used as model molecules to post-label ELA and BLA 
microbubbles.  For small molecules, such as NHS-FITC, the diffusion and binding to the 
tethered amino end groups were not affected by the PEG overbrush in BLA microbubbles, and 
the overall binding rate between ELA and BLA microbubbles was the same.  On the other hand, 
for macromolecules, such as SA-FITC, the diffusion and binding to the tethered biotin end 
groups were partially prevented by the PEG overbrush due to steric hindrances for BLA 
microbubbles, and the binding rate was significantly reduced.  The total binding capacity for 
BLA microbubbles was significantly lower for macromolecules in comparison to the ELA 
counterpart (~58%), suggesting a possible phase separation between lipid species on the surface.  
These results proved the hypothesis that small molecules could diffuse through the excluded 
volume of PEG chains and react with surface functional groups while larger molecules were 
significantly inhibited.  Post-labeling with BLA microbubbles is therefore highly feasible for 
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small ligands (<1 kDa) for generating targeted ultrasound contrast agents.  In addition, the effect 
of microbubble size on ligand conjugation was investigated.  It was shown that ligand 
conjugation was not affected by microbubble diameter regardless of the ligand size or 
microbubble surface architecture.  A new way of introducing complex surface structures, or 
wrinkles, was also discovered through streptavidin conjugation to ELA microbubbles.  It was 
proposed that the tight serpentine shape P gate and the event% parameter from the flow 
cytometry data can be used together with epi-fluorescence microscopy to detect these surface 
structures.  Flow cytometry can give a quick quantitative indication of the percent of 
microbubbles in a given suspension that deviate from the normal spherical shape, while 
microscopy offers direct visual confirmation of the surface structure. 
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Chapter 3: The Role of Poly(ethylene glycol) Brush Architecture on In Vitro 
Complement Activation for Targeted Microbubbles 
 
3.1. Introduction 
 For intravenously injected colloidal particles, such as ultrasound contrast agents, it is 
extremely important to ensure that they do not trigger any undesired immune response.  The 
incorporation of the flexible PEG polymer chains in the microbubble shell is designed to reduce 
the immunogenicity of these contrast agents by physically preventing the diffusion and 
attachment of complement proteins or antibodies to the microbubble surface in a similar fashion 
as for Stealth Liposomes.  However, recent studies have suggested that PEGylated liposomes are 
capable of triggering the complement system in human serum and fixing opsonic complement 
proteins (Moghimi and Szebeni 2003; Szebeni 2005; Moghimi, Hamad et al. 2006; Moghimi and 
Hamad 2008).  In addition, decorating microbubbles with targeting ligands could further present 
chemical groups that bind to complement C3 proteins and trigger CARPA.  Clearly, avoidance of 
an immunogenic response is desirable for targeted microbubbles, not only to minimize 
hypersensitivity reactions, but also to enable long circulation persistence for accumulation at the 
target site.  Ideally, the targeting ligand would be hidden from the milieu until the microbubble 
reaches the region of interest, where it is exposed for binding via multiple ligand-receptor 
interactions that result in firm adhesion. 
Microbubbles with the buried-ligand architecture may just offer the perfect solution for 
this issue.  As explained in the previous chapters, the targeting ligands are attached to the shorter 
PEG chains, and are buried in a longer PEG overbrush from exposing to the surrounding 
environment until reaching to the target site during circulation.  Because of the unique oscillation 
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property of microbubbles (expansion and contraction in response to an ultrasound field), the 
targeting ligands would only be revealed for adhesion during the acoustic pulse, and re-shielded 
at the end of each ultrasound cycle.  This stealth microbubble design has been shown to facilitate 
selective adhesion in combination with USRF without compromising binding specificity.  In an 
attempt to further experimentally test the effect of the PEG brush architecture on microbubble 
immunogenicity, microbubbles with various surface architectures were generated (Figure 3.1).  
Instead of using a pre-synthesized lipoprotein-peptide conjugate as one of the shell components, 
a post-labeling technique was utilized to conjugate RGD peptides to the tethered PEG chains 
after microbubble generation and isolation.  It has been demonstrated in the previous chapter that 
small molecules, such as the RGD peptide with its molecular weight <1 kDa, could diffuse freely 
through the PEG overbrush and bind to the tethered functional groups to generate targeted 
contrast agents.  In the present chapter, microbubbles with various PEG brush architectures were 
tested for immunogenicity in vitro.  By quantifying the amount of complement C3/C3b binding 
to the microbubbles after human serum incubation, evidence was shown that the buried-ligand 
design indeed decreased microbubble immunogenicity.  These findings further supported the 
utilization of the buried-ligand architecture to future designs of biocolloids as molecular imaging 
agents and drug delivery carriers. 
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Figure 3.1.  Cartoon illustrating microbubble surface architecture design for in vitro 
immunogenicity studies.  The PEG chain length was estimated using self-consistent field (SCF) 
theory (Lai and Zhulina 1992) as mentioned in Chapter 2. 
 
3.2. Materials and Methods 
3.2.1. Materials 
 All phospholipids were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL), 
including 1,2-distearyol-sn-glycero-3-phosphocholine (DSPC), 1,2-distearyol-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (DSPE-PEG2000), 1,2-distearyol-
sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)2000] (DSPE-PEG2000-
M), 1,2-distearyol-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)3000] 
(DSPE-PEG3000) and 1,2-distearyol-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)5000] (DSPE-PEG5000).  All phospholipids were dissolved in 
chloroform (Sigma-Aldrich; St. Louis, MO) and stored in the freezer at -20 ⁰C.  The 
perfluorobutane gas (PFB, 99 wt% purity) used for microbubble generation was purchased from 
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FluoroMed, L.P. (Round Rock, TX).  The RGD peptide (cyclo [Arg-Gly-Asp-D-Phe-Cys], 99.9% 
purity) was purchased from Peptides International (Louisville, KY) and was dissolved in 3 vol% 
degassed acetic acid (Sigma-Aldrich).  The dissolved RGD peptide was aliquoted into 50-μL 
volume and stored in nitrogen at -20 ⁰C.  The L-cysteine was purchased from Sigma-Aldrich and 
was dissolved in 18 MΩ-cm filtered deionized water (Direct-Q Millipore; Billerica, MA).  The 
L-cysteine solution was prepared on each day immediately before use to ensure reactivity. 
 Human complement-preserved serum was purchased from Valley Biomedical (catalog no. 
HC1004; Winchester, VA).  Serum was thawed once to aliquot into 1-mL eppendorf tubes and 
stored at -80 ⁰C.  Anti-human IgG-FITC antibody (catalog no. F4512) was purchased from 
Sigma-Aldrich.  Both anti-human albumin-FITC antibody (catalog no. CLFAG2140) and anti-
human C3/C3b-FITC antibody (catalog no. CL2103F) were purchased from Cedarlane 
(Burlington, NC).  All antibody solutions were stored at 4 ⁰C. 
 
3.2.2. Microbubble Generation and RGD Peptide Conjugation 
The compositions of microbubble samples are listed in Table 3.1.  Microbubbles were 
generated as described in Chapter 2 and elsewhere (Feshitan, Chen et al. 2009).  Briefly, the 
indicated amounts of each phospholipid species were mixed, and the chloroform was evaporated.  
The dried lipid film was hydrated with phosphate buffered saline (PBS) mixture (90 vol% 
PBS:10 vol% 1,2-propanediol:10 vol% glycerol; Sigma-Aldrich) to a final lipid/surfactant 
concentration of 1 mg/mL.  Fully dispersed lipid suspension was then transferred to a 3-mL 
serum vial and sealed for headspace PFB gas exchange.  Microbubbles were formed by shaking 
with a VialMix (ImaRx Therapeutics; Tucson, AZ) for 45 s.  The generated microbubbles were 
then diluted to 10-mL suspension with PBS, and washed 3 times by centrifugation flotation in a 
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bucket-rotor centrifuge (Model 5804, Eppendorf; Westbury, NY) at 250G for 5 min.  The 
microbubble cake was then diluted in 5 mM EDTA (pH 6.5) for subsequent experiments. 
 
Table 3.1. Microbubble compositions for in vitro immunogenicity studies 
 
Phospholipid Composition (mol %) 
Samples DSPC 
DSPE-
PEG2000 
DSPE-
PEG2000-M 
DSPE-
PEG3000 
DSPE-
PEG5000 
ELA-P2K Control 90 10 - - - 
ELA-P5K Control 90 - - - 10 
ELA 5% 90 5 5 - - 
ELA 0.5% 90 9.5 0.5 - - 
ELA 0.05% 90 9.95 0.05 - - 
BLA-P2K/P5K Control 90 5 - - 5 
BLA 5% 90 - 5 - 5 
BLA 0.5% 90 4.5 0.5 - 5 
BLA 0.05% 90 4.95 0.05 - 5 
BLA-P3K 5% 90 - 5 5 - 
      
An Accusizer optical particle counter (NICOMP Particle Sizing System; Santa Barbara, 
CA) was used to measure the size distribution and particle concentration.  The amount of RGD 
peptide needed was then calculated as described in the previous chapter.  RGD peptide was 
added to react with maleimide functional groups on the distal end of PEG chains at a molar ratio 
of 30:1 (RGD:maleimide).  The reaction was carried out on a benchtop rotator for 12 hours at 4 
⁰C.  To ensure there were no unreacted maleimide groups, L-cysteine was added at a molar ratio 
of 1000:1 (L-cysteine:maleimide) after regular RGD peptide conjugation. The sample was 
incubated on a benchtop rotator for 30 min at room temperature.  Unreacted RGD peptide was 
removed by centrifuging the microbubble suspension at 250G for 4 min.  The concentrated 
microbubble cake was then re-suspended in PBS and analyzed by Accusizer.  The median 
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fluorescence intensity was measured using an Accuri C6 flow cytometer (Accuri Cytometers Inc.; 
Ann Arbor, MI).  For zeta potential measurement, the washed microbubble cake was re-
suspended in pH adjusted PBS solution (pH 7.2) and analyzed using a Malvern Zetasizer Nano-
ZS (Malvern Instrument Ltd.; Worcestershire, UK). 
 
3.2.3. HPLC Analysis of RGD Coupling to Microbubbles  
RGD peptide conjugation was confirmed using HPLC and MALDI-TOF as reported 
elsewhere (Nallamothu, Wood et al. 2006; Liu, Ruan et al. 2010).  Two ELA microbubble 
samples were made: one with 1:1 RGD:maleimide molar ratio and one with 30:1 
RGD:maleimide molar ratio, following the same procedure as described above.  No L-cysteine 
was added to cap the unreacted maleimide groups at the end of the coupling reaction.  Upon 
reaction completion, the microbubble suspensions were sonicated at 60 ⁰C for 30 min using a 
bath sonicator (model 1510, Branson Ultrasonics; Danbury, CT) until the lipids were completely 
dispersed in solution.  HPLC injection samples were directly taken from the reaction vial without 
further filtering to ensure no RGD peptide was lost during handling.  The 30:1 molar ratio 
microbubble sample was diluted according to calculation using deionized water prior to HPLC 
analysis. 
The attachment of RGD peptides to the microbubble surface was ascertained indirectly 
by determining non-coupled peptide fraction using HPLC.  A Nova-Pak C18 column (4 µm, 3.9 x 
50 mm, Waters; Milford, MA) was used with a mobile phase consisting of 0.05% trifluoroacetic 
acid (TFA) in water (eluant A) and 0.05% TFA in acetonitrile (eluant B).  The eluant gradient 
was set from 10% to 60% B in 50 min and subsequently back to 10% B over 5 min.  Flow rate 
was set to 1 mL/min.  The column was equilibrated for at least 10 min with 90% A and 10% B 
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between measurements.  The uncoupled RGD peptide was detected by measuring absorbance at 
214 nm.  The detected peaks were collected for MALDI-TOF mass spectrometry analysis. 
 
3.2.4. MALDI-TOF Mass Spectrometry Analysis of HPLC Sample Peaks 
 The samples for the MALDI-TOF experiment were first freeze-dried and resuspended in 
5 µL 20% acetonitrile in water containing 10% TFA.  0.5 µL of the resulting solution was mixed 
with 2.5 µL of nitrogen saturated matrix solution.  The matrix solution was made by dissolving 
35 mg α-cyano-4-hydroxycinnamic acid in 0.8 mL of 50% acetonitrile in water containing 1% 
TFA.  2 µL of this mixture solution containing the HPLC sample was spotted on a stainless steel 
sampling plate and allowed to air dry.  The MALDI-TOF measurement was carried out on a 
Voyager-DE BioSpectrometry Workstation (PerSeptive Biosystems; Framingham, MA) with 
linear positive model.  The main instrumental settings were made manually, with typical voltage 
being 25,000 V, grid being 95 and delay time being 100 ns. 
 
3.2.5. Human Complement-Preserved Serum C3/C3b Activity Assay 
 Serum aliquots were randomly chosen from each batch to test for complement component 
C3/C3b activity at different time points throughout the entire immunogenicity study.  C3/C3b 
activity was measured using an ELISA kit purchased from Assaypro (catalog no. EC2101-1) 
following the manufacturer’s instruction.  No serum was re-frozen after ELISA assay to ensure 
complement activity. 
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3.2.6. Microbubble Serum Stability Analysis 
 1 mL serum was preheated in a water bath at 37 ⁰C using a digital block heater (VWR; 
West Chester, PA) for at least 20 min.  A total of 5x108 RGD-conjugated microbubbles were 
added to the serum, and the size distribution and microbubble concentration was continuously 
monitored for 2 hr at 37 ⁰C using both Accusizer and flow cytometer.  The same amount of 
sample (6 μL for Accusizer and 4 μL for flow cytometry) was taken out at different time points 
for measurement to ensure consistency.  Incubated samples were vortexed regularly to prevent 
microbubble aggregation at the top of the serum.  Flow cytometry size isolated gating was used 
for data analysis as described in the previous chapter. 
 
3.2.7. Microbubble Antibody Binding Analysis 
 A total of 5x108 microbubbles (about 100 μL in volume) were incubated with 900 μL 
serum on a benchtop rotator for 2 hr at room temperature.  The sample was then washed once by 
centrifugation floatation at 250G for 3 min.  The concentrated microbubble cake was re-
suspended in 100 μL PBS solution and analyzed by both the Accusizer and flow cytometer.  For 
anti-human C3/C3b, anti-human IgG and anti-human albumin FITC-antibody binding, 5 μg 
antibody was added.  All FITC-antibody binding experiments were carried out in the dark on a 
benchtop rotator for 1 hr at room temperature.  At the end of the incubation period, the 
microbubble sample was again analyzed by flow cytometry and microscopy without washing.  
The measured median fluorescence intensity data was analyzed according to microbubble 
diameter using size-isolated microbubble gating information as described in the previous chapter. 
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3.2.8. Optical Microscopy 
Direct visual confirmation of microbubble fluorescence was performed within 24 hrs 
after FITC antibody binding.  Microbubble samples were taken out of the reaction syringe and 
imaged at room temperature.  Still images were taken using an Olympus 1X71 inverted 
microscope (Olympus; Center Valley, PA).  Images in both bright field and epi-fluorescence 
mode were captured for the same field of view using a high-resolution digital camera (Orca HR, 
Hamamatsu; Japan) with a 100x oil immersion objective and processed with Simple PCI 
software (C-Imaging; Cranberry Township, PA).  Subsequent image analysis was done using 
ImageJ 1.4g software (NIH; Washington DC.). 
 
 
3.3. Results and Discussion 
3.3.1. Targeted Microbubble Generation 
 For each set of microbubble components, the vial shaking method produced a milky, 
white microbubble suspension that was stable over the experimental timeframe.  It has been 
shown in the previous chapter that small ligands with molecular weight < 1 kDa, such as RGD 
peptides, could diffuse freely through the PEG overbrush and react with functional groups at the 
distal end of buried PEG chains.  Here, HPLC and MALDI-TOF were used to ensure the 
complete attachment of RGD peptides to the surface of BLA microbubbles using the post-
labeling technique (see below).  Since several factors, such as microbubble size and surface 
charge, could influence the interactions between microbubbles and serum antibodies, the 
physicochemical properties of the samples were examined (Table 3.2).  Microbubble samples 
were matched in concentration after the RGD conjugation and/or washing steps.  We measured 
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similar size distributions for all samples, with a dominant peak between 1 and 2 μm and a 
secondary peak between 4 and 5 μm (Figure 3.2A and 3.2B).  The conjugation of RGD peptide 
to the surface of microbubbles did not affect either the microbubble size distribution or 
concentration.  The number-weighted mean diameters for all microbubble samples were found to 
be similar, while the volume-weighted mean diameters ranged between 4.7 and 8.2 μm.  
Measurement of zeta potential showed that the negative charge of P2K microbubbles tended to 
increase by the conjugation of RGD peptide at pH 7.2.  At the same time, the addition of the 
PEG overbrush (DSPE-PEG5000) into the microbubble shell tended to neutralize this negative 
charge. 
 
 
 
Table 3.2. Microbubble physicochemical properties 
 
Initial 
Concentration 
(#/mL) 
Number-Weighted 
Mean Diameter 
(μm) 
Volume-Weighted 
Mean Diameter 
(μm) 
 
 
Zeta Potential (mV) 
Samples (Mean) (Mean ± SD) (Mean ± SD) (Mean ± SD) 
ELA-P2K Control 5.19E+09 1.3 ± 0.0 5.4 ± 0.6 -24.1 ± 1.7 
ELA-P5K Control 4.19E+09 1.4 ± 0.1 6.7 ± 2.0 -9.50 ± 2.1 
ELA 5% 4.59E+09 1.4 ± 0.1 8.2 ± 2.1 -38.9 ± 2.8 
ELA 0.5% 6.10E+09 1.4 ± 0.0 6.9 ± 0.8 -31.4 ± 0.9 
ELA 0.05% 5.29E+09 1.3 ± 0.0 6.8 ± 0.4 -30.0 ± 1.1 
BLA-P2K/P5K Control 5.89E+09 1.4 ± 0.1 4.8 ± 0.8 -12.0 ± 0.6 
BLA 5% 4.83E+09 1.4 ± 0.1 5.2 ± 0.7 -19.2 ± 0.3 
BLA 0.5% 6.57E+09 1.5 ± 0.1 6.8 ± 0.6 -14.6 ± 0.8 
BLA 0.05% 6.78E+09 1.4 ± 0.1 7.0 ± 3.2 -12.5 ± 1.7 
BLA-P3K 5% 4.63E+09 1.3 ± 0.0 4.7 ± 0.3 -37.6 ± 0.2 
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Figure 3.2.  5% RGD peptide labeled microbubble size distribution (A, B) and concentration (C, D) 
change during human complement-preserved serum incubation at physiological condition.  The size 
distribution was continuously monitored for 2 hrs for both ELA (A) and BLA (B) microbubble 
samples.  With the exception that some smaller microbubbles (diameter <2 μm) showed a decrease 
in number detected over time, the majority of targeted microbubbles were stable during incubation 
with no significant change in size.  The total concentration, as measured by Accusizer (C) and flow 
cytometer (D), was plotted against time according to microbubble diameter ranges.  Both 
techniques showed data in good agreement; even though a concentration decrease was observed for 
both designs at the end of 2-hr incubation time, more than 70% of the targeted microbubbles were 
stable at 30 min, which was in the same time scale as for a typical ultrasound contrast imaging 
session. 
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3.3.2. HPLC Analysis of RGD Coupling to Microbubbles 
  An HPLC method was adapted to determine the extent of coupling of the RGD peptide to 
the microbubbles as previously described (Nallamothu, Wood et al. 2006; Liu, Ruan et al. 2010).  
The method involved detecting the amount of free RGD left in the microbubble suspension after 
the coupling reaction.  Standard RGD peptide dissolved in the mobile phase eluted at about 8-
min retention time (P1) as shown in Figure 3.3A.  This peak was monitored as the standard for 
the estimation of free RGD in the final microbubble formulations. 
 The reacted microbubble samples were injected to determine the extent of the coupling 
reaction.  To ensure the accuracy of a negative detection of the free RGD peak was due to the 
complete coupling reaction, rather than an instrumental sensitivity issue, the injection volume for 
each microbubble sample was calculated so that the amount of RGD peptide would be the same 
(1 μg RGD/injection) assuming no reaction took place.  As shown in Figure 3.3B, there was no 
significant peak for the free RGD around 8 min, indicating that there was no considerable 
amount of free RGD peptide left unreacted in the 1:1 molar ratio sample. 
 It was hypothesized that bound RGD to DSPE-PEG2000-M would give a different 
retention time than the free RGD peptide.  Figure 3.3C shows the HPLC spectrum of the 30:1 
molar ratio microbubble sample with known excess amount of free RGD peptide presented in 
solution (positive control).  As expected, the free RGD peak was observed at about 8-min 
retention time again, confirming the sensitivity of this analysis method to detect free RGD in the 
presence of RGD-lipid conjugates. 
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Figure 3.3.  HPLC analysis confirming RGD coupling to microbubbles.  (A) Standard RGD peptide 
injection showed free RGD had an around ~8-min retention time.  This peak was used as the 
standard for all subsequent injections to confirm the completion of the RGD-microbubble coupling 
reaction.  P2 (11-min retention time) was confirmed using MALDI-TOF to be impurities presented 
in the sample.  (B) 1:1 molar ratio microbubble sample showed no free RGD peak at 8 min, 
indicating that all RGD peptides were conjugated to the microbubble surface.  (C) 30:1 molar ratio 
microbubble sample (positive control) showed free RGD peak at 8 min, confirming the sensitivity of 
the analysis method to detect free RGD in the presence of RGD-lipid conjugates.  P3 (13-min 
retention time) was confirmed using MALID-TOF as cross-linked RGD peptides. 
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3.3.3. MALDI-TOF Mass Spectrometry Analysis of HPLC Sample Peaks 
 Two additional peaks were detected on the HPLC spectra: one at ~11-min retention time 
(P2) and one at ~13-min retention time (P3) (Figure 3.3).  MALDI-TOF analysis was done in 
order to delineate these peaks from the free RGD peak (Figure 3.4).  Figure 3.4A confirms that 
P1 was indeed the free RGD peptide.  Some cross-linking between RGD peptides was detected, 
which may occur during sample handing post RGD-microbubble coupling reaction.  P2 showed 
an unknown sample mass at around 700 m/z, which could be PBS salts or impurities presented in 
the microbubble samples (Figure 3.4B).  P3 contained both impurities and double-linked RGD 
peptides, which suggested that cross-linking of the RGD peptides occurred during the coupling 
reaction (Figure 3.4C). 
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Figure 3.4.  MALDI-TOF mass spectrometry results confirming the identities of HPLC sample 
peaks.  (A) P1 was confirmed as free RGD.  Some cross-linking between RGD peptides occurred 
shown as the doubled mass peak at around 1158 m/z.  (B) An unknown sample mass was detected in 
P2, which suggested to be either PBS salts or impurities presented in the microbubble samples.  (C) 
P3 was confirmed as the cross-linked RGD product. 
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3.3.4. Microbubble Serum Stability 
The stability of microbubbles with 5% RGD peptide during incubation in human serum at 
physiological temperature was investigated.  Figure 3.2A and 3.2B shows the size distribution 
change for ELA and BLA microbubbles, respectively, during the 2-hr incubation as measured by 
the Accusizer.  For both surface architectures, smaller microbubbles with diameter less than 2 
μm showed a decrease in number detected over time, while larger microbubbles showed no 
significant change.  The total microbubble concentration change was monitored using both the 
Accusizer and the flow cytometer (Figure 3.2C and 3.2D).  Both detection methods showed 
results that were in good agreement: a decrease in microbubble concentration was observed for 
both surface architectures at all size ranges at the end of 2 hrs, with the highest decrease being 59% 
and 53% for ELA and BLA 6-8 μm microbubbles, respectively.  However, the concentration 
decrease for all microbubble samples after 30 min incubation ranged from only 11% to 30%.  
Based on these results, it is concluded that targeted microbubbles, regardless of surface 
architecture, were stable in human serum during incubation at physiological temperature within 
the time scale for a typical ultrasound contrast imaging session (~30 min) (Borden, Zhang et al. 
2008). 
 
3.3.5. Human Serum Factor Binding to Microbubbles 
It has been reported that the concentration of serum strongly affects activation of the 
complement system (Toda, Kitazawa et al. 2008).  Therefore, undiluted complement-preserved 
human serum was used for all experiments.  To ensure the validity of the immunogenicity data, 
complement activity of the serum samples was continuously monitored by measuring 
complement component C3/C3b activity of randomly chosen serum aliquots throughout the 
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study.  Figure 3.5 shows the quantified C3/C3b activity as measured by ELISA assay for all 38 
samples.  The measured C3/C3b activity was 30 ± 16 μg/mL of serum (mean ± SD).  The human 
serum samples from different batches were statistically identical in terms of complement C3/C3b 
activity, and the aliquots were stable for the duration of the experiments.  By showing consistent 
complement activity, it is ensured that any measured C3/C3b binding difference in the 
immunogenicity study was due to the difference in complement activation by various 
microbubble samples, not due to batch-to-batch variability in serum C3/C3b activity. 
 
 
Figure 3.5.  ELISA results of complement component C3/C3b activity for human complement-
preserved serum aliquots.  Serum aliquots were randomly chosen to be tested throughout the 
immunogenicity experiments.  The average of measured C3/C3b activity was 30 ± 16 μg/mL of 
serum (mean ± SD). The human serum samples from different batches were statistically identical in 
terms of complement C3/C3b activity. 
 
Next, the binding of human complement component C3/C3b, IgG and albumin to 
targeted microbubbles with 5% RGD conjugated to the surface was investigated.  Sufficient 
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incubation time (2 hr) was given to allow the full exposure of microbubbles to the serum 
environment.  Detection of fluorescent antibodies by flow cytometry allowed an assessment of 
serum factor binding to the microbubble shells.  Figure 3.6 shows the median fluorescence 
intensity (MFI) values for 1-2 μm ELA and BLA microbubbles after incubation with human 
serum and FITC-antibodies.  The 1-2 μm size range was chosen because these microbubbles 
were the most abundant in all the samples and could correctly represent the MFI trend for the 
entire population.  All three serum factors were detected on the targeted microbubble samples.  
However, increases in MFI for IgG and albumin were small (<10%) compared to C3/C3b 
binding to ELA and BLA microbubbles (3.8-fold and 1.3-fold increase, respectively).  It was 
therefore concluded that complement C3/C3b was the main opsonin involved with the 
recognition of targeted microbubbles by the immune system. 
Epi-fluorescence microscopy images provided direct visual confirmation of FITC-
antibody binding to the surface of targeted microbubbles.  Only anti-human C3/C3b FITC-
antibody labeled targeted ELA microbubbles were visible under epi-fluorescence mode.  Figure 
3.7 shows both the bright field and epi-fluorescence images for the same field of view of these 
polydisperse microbubbles.  All microbubbles appeared to be stable during observation.  No 
visible changes, such as collapse, aggregate formation or vesiculation were observed for these 
microbubbles over the observation time period (typically around 10-15 min).  Almost all 
microbubbles visible under the bright field mode were also seen under the epi-fluorescence mode, 
indicating FITC-antibody binding to the surface.  There was no preferential binding due to 
microbubble size.  However, non-uniform FITC-antibody attachment was observed (see enlarged 
images), indicating heterogeneous binding of complement C3/C3b. 
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Figure 3.6.  Human serum factor binding to 5% RGD peptide labeled 1-2 μm microbubbles.  The 
median fluorescence intensity (MFI) was measured after RGD peptide conjugation, after 2 hrs 
human serum incubation and after 1 hr anti-human serum factor FITC-antibodies incubation.  All 
three serum factors were observed to bind to both targeted microbubbles.  However, only 
complement C3/C3b showed significant MFI increases (>284%); while IgG and albumin showed 
much less binding (maximum MFI increase was <29%).  “*” denotes a significant increase vs. the 
corresponding “RGD+Serum” measurement (p<0.05). 
 
Using streptavidin-FITC as model ligand, it was previously shown that the PEG 
overbrush does not completely eliminate macromolecule conjugation to the surface of 
microbubbles, suggesting the existence of two distributions of PEG-lipid conjugates on the 
microbubble surface (see Chapter 2).  In the present study, a small amount of C3/C3b binding to 
BLA microbubbles was observed, lending further support to our suggestion that such non-
uniform distributions of lipid molecules in the microbubble shell (e.g., domains and folds) may 
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yield incomplete shielding of the targeting ligands.  The heterogeneous fluorescence observed on 
the shell was another indication of the existence of such microstructural features (Figure 3.7). 
 
 
Figure 3.7.  Microscopic images of 5% RGD labeled ELA microbubbles after C3/C3b binding in 
both bright field (A) and epi-fluorescence (B) mode.  Both images show the same field of view.  
Enlarged images indicate microstructural features of non-uniform C3/C3b binding.  Scale bars 
correspond to 10 μm. 
 
3.3.6. Human Serum Complement C3/C3b Binding to Control Microbubbles 
Control microbubbles without RGD peptide were first tested for immunogenicity after 
human serum incubation (Figure 3.8).  Three different surface architectures were studied.  
Significantly lower MFI values were detected for P2K/P5K control than those for P2K control in 
all microbubble size classes.  P5K control microbubbles showed the lowest MFI among all three 
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control samples.  For the same methoxy DSPE-PEG surface coverage, the MFI for P5K control 
4-5 μm and 6-8 μm microbubbles was only 36% and 31%, respectively, of those for their 
corresponding P2K control groups.  These data suggest that some complement C3/C3b may be 
binding to the underlying phospholipid as well, and that the longer PEG reduces this effect 
(Moghimi, Hamad et al. 2006). 
It is commonly accepted that water-soluble, nonionic PEG can protect colloidal particles, 
such as microbubbles and liposomes, from aggregation and macromolecule adsorption due to the 
steric hindrance effect of the polymer brush; each PEG chain forms an impermeable “cloud” 
over the surface because of its large excluded volume, which inhibits most macromolecules from 
diffusing into the brush layer.  Here, evidence is shown to further support this conclusion: the 
incorporation of DSPE-PEG5000 into the microbubble shell forced the PEG chains to extend 
further away from the surface than either the DSPE-PEG2000 alone or the DSPE-PEG2000/5000 
mixture, therefore forming a thicker and denser protective layer against complement protein 
adsorption. 
For a given architecture, an increase in complement C3/C3b fixation with microbubble 
size was observed (Figure 3.8).  The increase in MFI was found to be proportional to 
microbubble surface area, indicating that the surface density of C3/C3b was independent of 
microbubble diameter.  This result was consistent across all microbubble samples, including 
those with RGD targeting ligands (see below).  In addition to the higher total complement 
fixation, the larger microbubbles could also render them more susceptible to splenic clearance, 
possibly resulting in shorter circulation persistence.  Interestingly, our group previously found 
that the echoes from untargeted 6-8 μm microbubbles persisted much longer in the mouse kidney 
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than their 1-2 μm or 4-5 μm counterparts, suggesting other mechanisms, such as gas core 
dissolution, may be at play (Sirsi, Feshitan et al. 2010). 
 
 
Figure 3.8.  Human complement C3/C3b binding to control microbubbles.  P2K/P5K control 
microbubbles showed significantly lower C3/C3b binding than P2K control in all microbubble size 
ranges.  P5K control microbubbles showed the lowest amount of C3/C3b binding, suggesting a 
thicker and denser protective layer was formed by the DSPE-PEG5000 chains than either DSPE-
PEG2000 or DSPE-PEG2000/5000 mixture.  “*” denotes a significant difference vs. the 
corresponding P2K control, and “#” denotes a significant difference vs. the corresponding P5K 
control (p<0.05). 
 
3.3.7. Effect of RGD Ligand Surface Density 
The complement fixation on targeted microbubbles was tested next.  Figure 3.9 shows the 
dependence of complement C3/C3b binding on RGD peptide surface density.  Targeted ELA 
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microbubbles showed more C3/C3b binding than targeted BLA microbubbles for all RGD 
peptide surface coverages.  For targeted ELA microbubbles, as the amount of conjugated RGD 
peptide increased, the binding of C3/C3b increased accordingly, indicating a correlated immune 
response (Figure 3.9A).  Complement binding was linearly dependent on microbubble surface 
area, and the slope (change of MFI per μm2) increased as the RGD surface density increased.  
However, this trend was not seen for targeted BLA microbubbles.  For each size class, the MFI 
did not increase significantly even when the amount of conjugated RGD peptide was increased 
by two orders of magnitude (Figure 3.9B).  These results agreed with the previous findings that 
the buried-ligand architecture protects the targeting ligands by inhibiting the adsorption of 
macromolecules to the microbubble surface (See Chapter 2).  Since the extent of opsonization 
dictates the degree of complement activation, we conclude that BLA microbubbles triggered less 
immune recognition than their ELA counterparts. 
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Figure 3.9.  RGD surface coverage and size dependence of complement C3/C3b binding to targeted 
ELA (A) and BLA (B) microbubbles.  For ELA microbubbles, higher RGD surface coverage led to 
more complement C3/C3b binding.  But for BLA microbubbles, the PEG overbrush successfully 
protected the RGD peptide; no significant increase of MFI values was detected when the RGD 
conjugation amount was increased by two orders of magnitude.  For both surface architectures, 
large targeted microbubbles (6-8 μm) showed significantly higher C3/C3b binding than smaller 
ones (1-2 μm and 4-5 μm), possibly due to the higher amount of RGD peptide presented on the 
surface.  “*” denotes a significant increase vs. the corresponding 4-5 μm sample with 5% RGD, and 
“#” denotes a significant increase vs. the corresponding 6-8 μm sample labeled with 0.5% RGD 
(p<0.05). 
 
To further investigate the role of targeting ligand presentation on human complement 
C3/C3b binding, MFI values were compared for targeted and control microbubbles with the 
same surface PEG brush layer configurations (Figure 3.10).  The 1-2 μm size range was used to 
represent the entire population of microbubbles.  The exposed-ligand architecture led to a 
significant increase in complement activity compared to the P2K control (3.8-fold increase for 
ELA 5% vs. 1.5-fold increase for P2K control).  It is suggested that this increase in C3/C3b 
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binding was due to the presence of RGD peptide on the surface, which interacts with 
complement proteins in serum.  C3 molecules contain unstable thioester bonds upon cleavage of 
C3a from C3b (Murphy, Travers et al. 2008).  RGD peptides contain such nucleophilic groups 
(e.g., the carbonyl group on Asp and the amino group on Arg), which could trigger the 
immobilization of C3/C3b molecules on the ELA microbubble surface and activate the 
alternative pathway.  The addition of RGD peptide to the surface of BLA microbubbles similarly 
led to a significant increase in C3/C3b binding.  However, when compared to ELA microbubbles, 
the increase was much lower (1.3-fold increase for BLA 5% vs. no increase for P5K control).  
Such a small difference in MFI suggested that the buried-ligand architecture indeed partially 
inhibited the binding of C3/C3b to the microbubble surface and decreased the immunogenicity of 
targeted microbubbles. 
 
 
 
 
 
101 
 
 
 
Figure 3.10.  Flow cytometric analysis of complement component C3/C3b binding to 5% RGD 
peptide labeled 1-2 μm microbubbles.  Significant binding occurred to RGD labeled ELA 
microbubbles in comparison with P2K control, suggesting the targeting ligand was immunogenic.  
BLA microbubbles also showed C3/C3b binding, indicating partial complement protein fixation.  
However, the increase of MFI value for targeted ELA microbubbles was much higher than that for 
BLA microbubbles, supporting our hypothesis that the buried-ligand architecture could indeed 
successfully shield the RGD peptide from complement recognition.  “*” denotes a significant 
increase vs. the corresponding “RGD+Serum” measurement, and “#” denotes a significant increase 
vs. P2K control (p<0.05). 
 
3.3.8. Effect of PEG Overbrush Height 
To further illustrate the protective role of PEG chains, the MFI for 5% conjugated RGD 
peptides for microbubbles with different overbrush lengths was compared (Figure 3.11).  In 
addition to the ELA and BLA-P5K design, a different bimodal brush layer using DSPE-
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PEG3000 to form a shorter PEG overbrush was tested for complement C3/C3b binding.  It was 
hypothesized that the shorter PEG overbrush would result in an intermediate inhibition of 
C3/C3b binding.  Indeed, for all three size ranges, BLA-P3K microbubbles showed a measured 
MFI value that fell between the values detected for ELA and BLA-P5K designs when the same 
amount of RGD peptide was conjugated to the surface.  For 6-8 μm microbubbles, there was no 
significant difference in C3/C3b binding between targeted BLA-P3K and BLA-P5K 
microbubbles. 
 
 
Figure 3.11.  Illustration of the effect of PEG overbrush height on complement C3/C3b fixation.  
For targeted microbubbles, BLA-P3K showed an intermediate MFI value, supporting the 
hypothesis that DSPE-PEG3000 chains formed an intermediate brush layer to protect the targeting 
ligand from the complement system.  “*” denotes a significant difference vs. the corresponding 
ELA 5% (p<0.05). 
 
103 
 
 
The buried-ligand architecture did not completely inhibit the binding of complement 
C3/C3b to the targeted microbubble surface, presumably due to the phase separation of the 
phospholipid species in the lipid monolayer coating the microbubble shell.  It is also possible that 
the transient excursion of the PEG polymer chains could bring the RGD ligands past the 
overbrush and result in complement recognition.  However, when compared to targeted ELA 
microbubbles with the same amount of RGD conjugated to the surface, the amount of C3/C3b 
binding for BLA microbubbles was significantly reduced (~ -52% and ~ -68% for BLA-P3K and 
BLA-P5K, respectively, for 5% RGD peptide).  It is presumably the combined effect of the PEG 
overbrush shielding the RGD peptide and inhibiting C3/C3b fixation on the microbubble surface 
that resulted the reduced complement activation.  Therefore, it is concluded that the buried-
ligand architecture successfully protects RGD peptides on the surface of microbubbles from 
complement recognition, and targeted BLA microbubbles are significantly less immunogenic 
than ELA microbubbles in vitro. 
 
3.3.9. Effect of Microbubble Surface Charge 
 Finally, the effect of surface charge on human complement fixation was investigated.  
Figure 3.12 shows the human complement C3/C3b binding plotted against the measured average 
zeta potential (Table 3.2) for all microbubble formulations within the 1-2 μm diameter range.  A 
weak correlation between microbubble zeta potential and complement C3/C3b fixation was 
observed: as the negative zeta potential increased, there was more C3/C3b binding on the 
microbubble surface.  It has been previously reported that high surface charge (either positive or 
negative) promotes complement activation (Chonn, Cullis et al. 1991).  Here, similar findings 
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were observed to support this hypothesis.  However, it is necessary to point out that complement 
fixation is a complex interplay of long and short range interactions between the C3/C3b molecule 
and the microbubble surface groups, and it therefore is likely that the combined effect of surface 
charge and details of the PEG brush dictate the binding of complement protein molecules.  More 
experimental studies will be required to distinguish these two effects. 
 
 
Figure 3.12.  Illustration of the effect of microbubble surface charge on complement C3/C3b 
fixation.  Higher negative zeta potential led to a higher complement C3/C3b binding, suggesting a 
weak correlation between microbubble surface charge and complement activation. 
 
3.4. Conclusion 
 Complement activation-related pseudoallergy (CARPA) is an important adverse effect 
that has been observed clinically with non-targeted ultrasound contrast agents.  Increased 
incidence of CARPA arising from immunogenic groups on targeted microbubbles is therefore a 
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significant safety concern for the viability of ultrasound molecular imaging.  In this study, the 
immunogenicity of the targeted microbubbles with various surface architectures and ligand 
surface densities was investigated.  Targeted microbubbles with either the exposed- or buried-
ligand architecture (ELA or BLA, respectively) were generated using a post-labeling technique, 
and it was shown that they were stable during incubation in human complement-preserved serum 
at physiological conditions for at least 2 hrs with minimal change in size distribution or 
concentration.  Three serum factors (albumin, IgG and complement C3/C3b) were tested for 
microbubble binding, and only C3/C3b binding was detected using our system.  Even though 
RGD peptide is a physiological ligand, it was shown that it could still trigger an immune 
response when conjugated to the surface of microbubbles.  However, the PEG overbrush on the 
surface of BLA microbubbles partially inhibited the recognition of RGD peptide by the 
complement system and, therefore, reduced the ligand-mediated immunogenicity.  When the 
surface coverage of RGD peptide was increased by two orders of magnitude, C3/C3b binding 
was increased significantly for ELA microbubbles, while it stayed relatively constant for BLA 
microbubbles.  In addition, evidence of the protective role of the PEG overbrush on complement 
C3/C3b fixation was observed by showing that P5K control microbubbles had the lowest C3/C3b 
binding and that BLA-P3K microbubbles could still partially inhibit complement binding even 
with a shorter PEG overbrush layer.  The results presented in this Chapter show that the BLA 
strategy offers a means of targeting microbubbles without increasing complement activation and 
suggest that further studies are warranted to investigate the in vivo molecular imaging 
capabilities of such microbubbles. 
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Chapter 4: Effect of Poly(ethylene glycol) Brush Architecture on In Vivo 
Microbubble Circulation Persistence 
 
4.1. Introduction 
 In order to improve the contrast sensitivity of imaging targeted microbubbles for 
molecular imaging applications, many attempts have been made to improve the targeting ligand 
and adhesion schemes and microbubble detection methods (Dayton and Ferrara 2002; Zhao, 
Borden et al. 2004; Borden, Sarantos et al. 2006; Dayton and Rychak 2007; Zhao, Kruse et al. 
2007).  Since the acoustic behavior of microbubbles is highly dependent on their size, more 
recently, research focus has been shifted to improve the echogenicity of the contrast agents 
themselves.  Talu et al. (Talu, Hettiarachchi et al. 2007) used a flow focusing technique to 
produce monodisperse microbubbles and demonstrated their potential for enhanced contrast 
sensitivity in vitro by showing high correlation between microbubble echogenicity and size 
distribution.  In an in vivo experiment, Sirsi et al. (Sirsi, Feshitan et al. 2010) measured the 
contrast enhancement of non-targeted microbubbles in mouse kidneys using high frequency 
ultrasound and showed that their contrast-to-tissue signal could be improved based on 
microbubble size and concentration. 
In addition to contrast enhancement, microbubble circulation persistence is also directly 
correlated to their size.  In the same experiment, Sirsi et al. (Sirsi, Feshitan et al. 2010) also 
found that large microbubbles persisted in circulation much longer than smaller ones.  However, 
when the injected gas volume was matched, all microbubble sizes showed a similar persistence 
half-life.  In an similar experiment using rat models, Streeter et al. (Streeter, Gessner et al. 2010) 
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showed supporting results that size-sorted 3 μm microbubble produced at least 3 times longer 
circulation time than size-sorted 1 μm and unsorted samples when imaged at lower frequency.  
All these findings indicated that the dissolution of the microbubble gas core played a larger role 
in contrast elimination than the filtering by the lungs and spleen during circulation (Kabalnov, 
Klein et al. 1998; Sirsi, Feshitan et al. 2010). 
Many studies have been performed to investigate the effect of surface chemistry on the 
circulation persistence of biocolloids.  Hydrophilic polymers, such as PEG chains or PEG chain 
derivatives, have long been incorporated into the surface of liposomes in order to prolong their 
circulation time owing to the polymeric steric hindrance effect (Immordino, Dosio et al. 2006).  
Phillips et al. (Phillips, Klipper et al. 1999) demonstrated that by adding 10 mol% DSPE-
PEG5000 chains into the formulation, the persistence half-life of liposome-encapsulated 
hemoglobin was increased by greater than 3-fold when compared to non-PEG-containing 
formulations.  More recently, du Toit et al. (du Toit, Govender et al. 2011) showed that the 
persistence of lipid nanobubbles could be enhanced by changing the surface charge with a 
polymeric anionic hydrogel shell.  Interestingly, Fisher et al. (Fisher, Christiansen et al. 2002) 
showed different findings with lipid microbubbles.  Using intravital microscopy, he 
demonstrated that the addition of negative charge on the surface of microbubbles could decrease 
their circulation time in the capillaries by increasing complement-mediated attachment to the 
endothelium.   
The present study is to extend previous work on the stealth microbubble design, in which 
targeted microbubbles with various surface architectures were studied for their in vivo contrast 
enhancement and circulation persistence.  Size isolated microbubbles with different surface 
architectures (Figure 4.1) were generated in order to eliminate the size effect on their circulation 
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behavior.  RGD peptide was used as the targeting ligand to simulate a relevant biomarker for 
tumor progression.  The microbubble contrast enhancement properties were examined in mouse 
models using a commercially available high frequency ultrasound scanner.  It has been 
previously reported that there is a close correlation between complement activation in vitro and 
in vivo using animal models (Ishida, Kojima et al. 2000).  Based on the results presented in 
Chapter 3, it was assumed that the buried-ligand architecture could effectively reduce 
complement activation in vivo and therefore decrease the microbubble elimination rate.  The 
results presented in this chapter are relevant to contrast-enhanced small animal imaging and offer 
insights for generating stealth ultrasound contrast agents using the buried-ligand architecture 
design. 
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Figure 4.1.  Cartoon illustrating microbubble surface architecture design for in vivo perfusion 
imaging studies.  The PEG chain length was estimated using self-consistent field (SCF) theory (Lai 
and Zhulina 1992) as mentioned in Chapter 2. 
 
4.2. Materials and Methods 
4.2.1. Materials 
 Phospholipids were purchased from either Avanti Polar Lipids, Inc. (Alabaster, AL) or 
NOF America Corporation (White Plains, NY), including 1,2-distearyol-sn-glycero-3-
phosphocholine (DSPC), 1,2-distearyol-sn-glycero-3-phosphoethanolamine-N-
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[methoxy(polyethylene glycol)2000] (DSPE-PEG2000), 1,2-distearyol-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)2000] (DSPE-PEG2000-M) and 1,2-
distearyol-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)5000] (DSPE-
PEG5000).  All phospholipids were stored in the freezer at -20 ⁰C.  The perfluorobutane gas 
(PFB, 99 wt% purity) used for microbubble generation was obtained from FluoroMed, L.P. 
(Round Rock, TX).  The RGD peptide (99.9% purity) was purchased from Peptides International 
(Louisville, KY) and was dissolved in 3 vol% degassed acetic acid (Sigma-Aldrich).  The 
dissolved RGD peptide was aliquoted into 50-μL volume and stored in nitrogen at -20 ⁰C. 
 
4.2.2. Microbubble Generation and Size Isolation 
 The compositions of microbubble samples for all the experiments performed are listed in 
Table 4.1.  Microbubbles were generated using the probe sonication method as described 
elsewhere (Feshitan, Chen et al. 2009).  Briefly, the indicated amounts of each phospholipid 
species were mixed and hydrated with a phosphate buffered saline (PBS) mixture (90 vol% 
PBS:10 vol% 1,2-propanediol:10 vol% glycerol; Sigma-Aldrich) to a final lipid/surfactant 
concentration of 2 mg/mL.  The lipid solution was heated in a water bath at ~65 ⁰C for 15 min, 
and then sonicated with a 20 kHz probe (model 250A, Branson Ultrasonics; Danbury, CT) at low 
power (power setting dialed to 3/10; 3W) in order to heat the lipid suspension above the DSPC 
main phase transition temperature (~ 55 °C) and further disperse the lipid aggregates into small, 
unilamellar liposomes.  PFB was introduced by flowing it over the surface of the lipid 
suspension.  Subsequently, high power sonication (power setting dialed to 10/10; 33 W) was 
applied to the suspension for about 10 s at the gas-liquid interface to generate microbubbles.  The 
111 
 
 
generated microbubbles were concentrated by centrifugation flotation in a bucket-rotor 
centrifuge (Model 5804, Eppendorf; Westbury, NY) at 300G for 3 min.  The infranatant, which 
contained residual lipids and vesicles that did not form part of the microbubble shells, was 
recycled to produce the next batch of microbubbles.  All resulting microbubble cakes were 
combined and re-suspended in PBS to improve total yield. 
 
Table 4.1. Microbubble compositions for in vivo perfusion imaging studies 
 
Phospholipid Composition (mol %) 
Samples DSPC DSPE-PEG2000 DSPE-PEG2000-M DSPE-PEG5000 
ELA Control 90 10 - - 
ELA 90 - 10 - 
BLA Control 90 5 - 5 
BLA 90 - 5 5 
 
 
 The microbubble size isolation method was used as first introduced by Feshitan et al. 
(Feshitan, Chen et al. 2009).  A brief description of the size isolation protocol is presented here.  
After combining all the initial cakes, microbubbles with diameter less than 4 μm were removed 
by centrifuging at 110G for 1 min.  The cake was collected and re-suspended in PBS, while the 
infranatant was discarded.  This washing step was repeated 5-7 times to fully ensure all the 
smaller microbubbles were removed from the sample.  Microbubbles with diameter greater than 
5 μm were removed by centrifuging at 70G for 1 min.  The infranatant containing 4-5 μm 
microbubbles was collected, and the cake was discarded.  The collected infranatant was 
centrifuged again at 120G to concentrate the sample.  This step was repeated 3-5 times to ensure 
a sufficient number of 4-5 μm microbubbles were collected.  The final concentrated 4-5 μm 
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microbubble sample (concentration >1×109 #/mL) was then re-suspended in 1 mL PBS and 
stored in room temperature overnight.  Although we have previously shown that size isolated 
microbubble samples were stable at 4 ⁰C for at least 2 weeks (Feshitan, Chen et al. 2009), all the 
microbubble samples used for this study were freshly prepared within 24 hrs to ensure 
experimental consistency. 
 
4.2.3. RGD Peptide Conjugation to Targeted Microbubbles 
 To generate targeted microbubbles, the final concentrated 4-5 μm microbubble cake was 
re-suspended in 1 mL PBS mixed with 5 mM EDTA (pH 6.5).  A Coulter Multisizer III particle 
counter (Beckman Coulter; Opa Locka, FL) with a 50 μm aperture was used to measure the size 
distribution and particle concentration.  The amount of RGD peptide needed was then calculated 
as previously described (Chen and Borden 2010).  RGD peptide was added to react with 
maleimide functional groups on the distal end of PEG chains at a molar ratio of 30:1 
(RGD:maleimide).  The reaction was carried out on a benchtop rotator for 12 hours in room 
temperature.  Unreacted RGD peptide was removed by centrifuging the microbubble suspension 
at 110G for 1 min.  The concentrated microbubble cake was then re-suspended in PBS and 
analyzed by the Multisizer. 
 
4.2.4. Animal Preparation and Handling 
All animals were handled according to the National Institute of Health guidelines, and 
our experimental protocol was approved by the Columbia University Institutional Animal Care 
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and Use Committee.  Female CD-1 mice between 4 to 8 weeks of age (Charles River 
Laboratories; Wilmington, MA) were used for the contrast persistence studies.  Before imaging 
an animal, it was first anesthetized in an induction chamber using aerosolized 2% isoflurane-
oxygen mixture.  Once sedated, it was placed on a heated mouse handling table while 
continuously breathing 1% to 2% isoflurane-oxygen mixture via nosecone delivery for the 
duration of the experiment.  The animal heart rate, respiratory rate and temperature were 
monitored using a TMH-150 physiological monitoring unit (VisualSonics; Toronto, Ontario, 
Canada).  The mouse was placed in the prone position, and its back was shaved with an electric 
clipper.  A depilatory cream was applied to the animal skin to dissolve any remaining hair that 
would interfere with the ultrasound imaging.  A modified 27-gauge 1½ butterfly catheter 
(Terumo Medical Corporation; Somerset, NJ) was inserted into the mouse’s tail vein for 
microbubble injections.  A Vevo 770 small animal ultrasound imaging scanner with a 40-MHz 
imaging transducer (VisualSonics) was placed over the kidney region and coupled with 
Aquasonic-100 ultrasound transmission gel (Parker Laboratories; Fairfield, NJ) to ensure the 
quality of signal transmission.  Figure 4.2 shows an actual image taken of a prepared mouse on 
the imaging platform ready for microbubble injection.  After the mouse regained consciousness 
at the end of each imaging session, it was returned to its cage. 
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Figure 4.2.  A prepared mouse on the imaging platform ready for microbubble injection. 
 
4.2.5. Microbubble Injection and Image Acquisition 
 A 500 μL diluted microbubble suspension at 1×10 8 #/mL concentration in sterilized 0.9% 
NaCl saline solution (Hospira, Inc.; Lake Forest, IL) was freshly made before each animal 
injection.  A 50 μL bolus injection of the diluted microbubble sample, followed immediately by 
50 μL sterilized saline flushing solution, was injected while imaging data was continuously 
acquired.  The mouse kidneys were selected as the imaging location for this study because of the 
proximity to the skin surface and the high concentration of vasculature.  Contrast mode images 
were collected while respiratory gating was applied in synchronization with the mouse 
respiratory cycle to reduce motion artifact during data analysis.  The effective frame rate during 
image acquisition was between 1-2 frames/sec.  At the focal length (6 mm), the peak negative 
pressure is 3.49 MPa with an acoustic power of 0.017 mW and a mechanical index of 0.57 
(VisualSonics Vevo 770 High-Resolution Imaging System Operator Manual).  The time-gain 
compensation (TGC) settings were kept at a value of 10 throughout all imaging sessions to 
ensure signal linearization during data analysis.  The video data was collected prior to a bolus 
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injection of microbubbles, and was continued for up to 30 min to allow the majority of the 
microbubbles to be cleared by the animal.  If there were still microbubbles visibly circulating in 
the bloodstream, the image acquisition was prolonged to accommodate for the longer persistence.  
Figure 4.3 shows typical images of the mouse kidney before and after a bolus injection of 
microbubble contrast agents.  Only one microbubble injection was given to the same mouse 
during each imaging session to minimize effects of a potential immune response caused by 
repeated injections (n = 6-8 per group). 
 
 
Figure 4.3.  Typical images of the mouse kidney before (A) and after (B) a bolus injection of 
microbubbles.  The kidney region is outlined in white.  Significant increase of contrast signal was 
observed as speckles within the kidney region.  Arrows point out the microbubble shadowing effect 
due to signal attenuation. 
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4.2.6. Data Analysis 
 All image analyses were done using either the Vevo 770 application software 
(VisualSonics) or a custom developed image processing program in LabVIEW (National 
Instruments Corporation; Austin, TX).  Two sets of regions of interest (ROIs) were selected and 
analyzed to ensure data consistency (Figure 4.4).  In the first set, one large ROI in the upper 
portion of the kidney was selected so that it gave the maximum increase of signal intensity while 
minimizing effects of signal attenuation and microbubble shadowing (Figure 4.4B).  In the 
second set, multiple ROIs were drawn across different regions of the kidney (Figure 4.4C).  The 
multiple ROIs were divided into two groups: three in the upper region and three in the lower 
region of the kidney.  The measured signal intensity was averaged within these two groups, and 
the final values were used for analysis.  All images were examined to ensure there was no gross 
movement of the kidney to cause ROI shifting.  The contrast enhancement was calculated using 
the mean grayscale video intensity determined by integrating the pixel intensity values over the 
ROI in every acquired frame.  All computed contrast enhancement data sets were baseline 
adjusted and plotted using Prism 5 graphing software (Graphpad Software, Inc.; La Jolla, CA) 
for data fitting. 
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Figure 4.4.  Typical ultrasound images of the mouse kidney showing the drawings of two sets of 
regions of interest (ROIs) following two different selection criteria.  (A) The original image of the 
kidney.  (B) The image of the kidney with one large ROI selected in the upper portion.  (C) The 
image of the kidney with multiple smaller ROIs selected across different regions of the kidney. 
 
Two pharmacokinetic drug persistence models were used to describe microbubble 
perfusion in the kidney: a single-compartment model as described by Saltzman (Saltzman 2001; 
Sirsi, Feshitan et al. 2010) (Equation 4.1) and a two-compartment model as described by Sirsi et 
al. (Sirsi, Hernandez et al. 2011) (Equation 4.2 – 4.4).  The single-compartment model assumes 
common first-order kinetics for the spreading and elimination, and uniform distribution of an 
intravenously injected drug in a single compartment.  Slow absorption is taken into consideration 
to represent the entry of the drug into the compartment.   
𝐶(𝑡) = 𝐶0𝑘1
𝑘2−𝑘1
(𝑒−𝑘1𝑡 − 𝑒−𝑘2𝑡)       Equation 4.1 
where C is the relative amount of measured contrast enhancement; C0 is the initial amount of 
contrast; k1 is a first order rate constant describing the influx of the contrast agent into the system; 
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k2 is a first order rate constant describing the elimination of the contrast agent from the system 
and t is the contrast persistence time. 
The two-compartment model assumes that, after the drug is injected rapidly into the body, 
it is slowly distributed throughout one compartment while irreversibly accumulated in a second 
compartment.  A first-order kinetic is used to describe the accumulation of the drug that 
contributes to its elimination from free circulation, and the total concentration of the drug is a 
combination of that in both compartments. 
𝐶(𝑡) = 𝐶1(𝑡) + 𝐶2(𝑡)         Equation 4.2 
𝐶1(𝑡) = 𝐶0𝑘1(𝑘2+𝑘3)−𝑘1 �𝑒−𝑘1𝑡 − 𝑒−(𝑘2+𝑘3)𝑡�       Equation 4.3 
𝐶2(𝑡) = 𝐶0𝑘1𝑘3 � 𝑒(𝑘4−𝑘1)𝑡−1𝑘12−𝑘1𝑘2−𝑘1𝑘3−𝑘1𝑘4+𝑘2𝑘4+𝑘3𝑘4 + 𝑒(𝑘4−𝑘3−𝑘2)𝑡−1𝑘22+𝑘32−𝑘1𝑘2−𝑘1𝑘3+𝑘1𝑘4+2𝑘2𝑘3−𝑘3𝑘4�   
           Equation 4.4 
where C1 is the relative amount of measured contrast enhancement from the intravascular 
compartment (compartment 1); C2 is the relative amount of measured contrast enhancement from 
the non-circulating microbubbles (compartment 2); k3 is a first order rate constant describing the 
efflux from compartment 1, which is the same as the influx into compartment 2 and k4 is a first 
order rate constant describing the elimination of microbubbles from compartment 2.  All curve 
fitting parameters, such as amplitude, persistence half-life, decay rate and total integrated signal 
enhancement (Area Under the Curve or AUC) , were obtained using the nonlinear regression tool 
in Prism 5 software.  All statistical analyses were also performed using Prism 5 software. 
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4.3. Results 
4.3.1. Microbubble Size Distribution 
 For each set of microbubble components, the probe sonication method produced a milky, 
white microbubble suspension that was stable over the experimental timeframe.  Freshly made 
microbubble suspensions were highly polydisperse in size as measured by the Multisizer.  Figure 
4.5 compares the number- and volume-weighted size distributions between freshly made and 
size-isolated ELA microbubbles as an example.  Other microbubble formulations showed similar 
size distributions.  For a freshly sonicated microbubble suspension, the number-weighted size 
distribution showed that most of the microbubbles (>90%) were smaller than 4 μm in diameter.  
Interestingly, the Multisizer measurement did not show distinct peaks (at 1-2 μm, 4-5 μm and 6-8 
μm) to indicate a multimodal size distribution in either number- or volume-weighted data as we 
previously reported using the Accusizer (Feshitan, Chen et al. 2009). 
The size isolation method developed by Feshitan et al. (Feshitan, Chen et al. 2009) uses 
centrifugation flotation to allow a rapid and efficient size selection of microbubbles and reduce 
sample polydispersity.  Figure 4.6 shows the number- and volume-weighted size distributions 
after size isolation for all microbubble samples as measured by the Multisizer, and Table 4.2 lists 
the initial concentration, mean diameter and injected gas volume for all four microbubble groups.  
In order to ensure stability, the concentrations of all microbubble samples were maintained above 
1×109 #/mL before injection.  In Chapter 2, it was shown that small ligands with molecular 
weight <1 kDa, such as RGD peptides, could diffuse freely through the PEG brush layer and 
react completely with the functional groups at the distal end of the PEG chains.  The conjugation 
of RGD peptide to the surface did not affect either microbubble size distribution or concentration.  
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There was no significant difference in the injected gas volume, which was calculated based on 
the volume-weighted mean diameter, between the four microbubble groups. 
 
 
Figure 4.5.  Typical microbubble number- (A) and volume-weighted (B) size distributions before 
and after size isolation.  Freshly made microbubble suspensions were highly polydisperse, with 
most of the microbubbles (>90%) smaller than 4 μm (based on number-weighted size distribution).  
Interestingly, no obvious multimodal size distribution with distinct size peaks was observed for 
microbubble samples measured by the Multisizer, as apposed to the previous measurements made 
using the Accusizer (see Chapter 2 and Feshitan et al. (Feshitan, Chen et al. 2009)). 
 
Table 4.2. Microbubble size distributions and concentrations 
 
Initial Concentration 
(#/mL) 
Number-Weighted 
Mean Diameter (μm) 
Volume-Weighted 
Mean Diameter (μm) 
Injected Gas Volume 
(μL) 
 Samples (Mean) (Mean ± SD) (Mean ± SD) (Mean) 
ELA Control 3.93E+09 4.3 ± 0.1 5.0 ± 0.0 0.32 
ELA 2.39E+09 4.2 ± 0.2 4.9 ± 0.1 0.31 
BLA Control 2.09E+09 4.4 ± 0.2 5.2 ± 0.1 0.37 
BLA 2.04E+09 4.0 ± 0.2 4.8 ± 0.2 0.29 
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Figure 4.6.  Microbubble number- (A) and volume-weighted (B) size distributions after size 
isolation by differential centrifugation.  Neither the various surface architectures nor the presence 
of the targeting RGD peptide on the surface affected the size distribution.  All detailed mean 
diameter and concentration values are listed in Table 4.2. 
 
4.3.2. ROI Selection 
 In order to ensure that the selection of ROIs correctly represented the signal change of the 
entire kidney, two sets of ROIs were drawn for analysis following two different selection criteria 
(Figure 4.4).  Time-intensity curves (TICs) of both sets of ROIs were generated for comparison 
to ensure data consistency.  The TICs were calculated using the contrast detection software 
(VisualSonics or LabVIEW) by integrating the image pixel intensities over the ROI.  Figure 4.7 
shows typical TICs generated from the single large ROIs in the upper portion of the kidney for 
each microbubble formulation together with the fitted one-compartment pharmacokinetic 
contrast persistence model lines.  Both ELA Control and BLA Control microbubbles gave 
similar persistence in circulation.  The TICs for BLA microbubbles were typically very similar to 
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the ones for BLA Controls, with similar contrast enhancement level and persistence time, while 
for ELA microbubbles, the observed circulation time was noticeably shorter. 
 
 
Figure 4.7.  Typical time-intensity curves (TICs) generated using the single large ROIs in the upper 
portion following bolus injections of microbubbles with various surface architectures.  
Representative TICs are shown for each microbubble formulation tested.  All data was baseline 
corrected using background images before injections as the corresponding references.  The fitted 
one-compartment pharmacokinetic model was shown as solid lines. 
 
 A second set of TICs were generated using the averaged intensity values from the 
multiple smaller ROIs in both the upper and lower portions of the kidney.  Figure 4.8 compares 
representative TICs for all microbubble formulations.  It can be clearly seen that the lower ROIs 
(red ROIs in Figure 4.4C) typically showed much less maximum signal intensities when 
compared to the upper ROIs (white ROIs in Figure 4.4C), ranging between 20% and 65% of 
those for the upper ROIs for each microbubble group.  This was attributed to the signal 
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attenuation (shadowing effect) from the microbubbles in the upper portion of the kidney.  As a 
result, the signal increase detected in the lower portion was significantly reduced and could not 
be used to correctly represent the signal change of the entire tissue.  Therefore, only the upper 
portion of the kidney was used to characterize microbubble contrast enhancement and 
persistence during data analysis. 
 
4.3.2. High Frequency In Vivo Imaging 
  All mice were given 50 μL bolus injections of microbubbles at 1×108 #/mL concentration.  
Images of the animal’s left kidney were continuously recorded during the bolus injection using a 
high-resolution small animal imaging scanner in the fundamental mode with a 40-MHz 
transducer.  Figure 4.9 shows representative ultrasound images of the mouse kidney before and 
after a bolus injection of ELA microbubbles.  The ROI used to calculate the contrast intensity 
change is outlined in white.  Figure 4.9A is the background image of the kidney before 
microbubble injection.  Figure 4.9B is the image taken at the peak amplitude of the signal 
intensity with grayscale contrast, which typically occurred 60-90 s after the bolus injection was 
given, and Figure 4.9C is the same image using the contrast detection software (VisualSonics) to 
highlight the increase of video intensity after microbubble injection. 
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Figure 4.8.  Representative averaged time-intensity curves (TICs) obtained using the smaller ROIs.  
Significantly reduced maximum signal intensities were observed in the lower ROIs for all 
microbubble groups, indicating microbubble-induced attenuation.  All subsequent two-
compartment model fitting was done using the averaged signal intensities calculated from the upper 
ROIs only.  (A) ELA Control.  (B) ELA.  (C) BLA Control.  (D) BLA. 
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Figure 4.9.  Representative ultrasound images of the mouse kidney showing contrast enhancement 
before (A) and after (B, C) a bolus injection of ELA microbubbles.  The region-of-interest was 
outlined in white and used for the time-intensity curve analysis.  (A) The background image of the 
mouse kidney before injection.  (B) Grayscale contrast image of the same kidney at the peak signal 
intensity, typically occurred 60-90 s after the bolus was given.  (C) The same image using contrast 
detection software to highlight the presence of microbubbles. 
 
All four microbubble groups showed noticeable positive contrast enhancement after the 
bolus injections.  The increase of brightness and speckling was observed evenly throughout the 
tissue in the ROI.  The change of signal intensity calculated using the contrast detection software 
gave similar measurements between ELA and BLA samples, regardless of the presence of the 
targeting ligands, indicating that the surface architecture of the microbubbles did not affect the 
signal enhancement ability of these contrast agents. 
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4.3.3. One-Compartment Pharmacokinetic Model 
 The one-compartment pharmacokinetic model described by Saltzman (Saltzman 2001) 
was first used to analyze the TICs generated using the single large ROIs in order to determine the 
signal amplitude and contrast persistence half-time for microbubbles with different surface 
architectures.  The model assumes that microbubbles are intravascular only during free 
circulation, and there is no passive accumulation of contrast agents onto or outside the 
vasculature.  While these assumptions may not fully describe the kinetics of microbubble influx 
and clearance in circulation, the model fits the data generally well, with typical R2 > 0.90, and 
allows the quantification and comparison of several important pharmacokinetic parameters such 
as the maximum intensity enhancement and the exponential microbubble elimination rate 
constant. 
 Positive contrast enhancement was detected for all microbubble samples.  Figure 4.10 
compares the grayscale signal amplitude among the four microbubble groups.  The signal 
amplitude was determined by the maximum signal intensity increase using the TICs.  There was 
no significant difference in signal amplitude between exposed and buried surface architectures as 
determined by a Students’ t-test (P = 0.50 for ELA Control vs. BLA Control).  In addition, the 
presence of the targeting ligand did not affect the signal amplitude (P = 0.18 for ELA Control vs. 
ELA and P = 0.88 for BLA Control vs. BLA), indicating that the contrast enhancement ability of 
microbubbles as ultrasound contrast agents was mainly dependent on microbubble diameter, or 
the gas core volume, not the surface structure of the monolayer phospholipid shell. 
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Figure 4.10.  Maximum microbubble signal intensity obtained using the one-compartment 
pharmacokinetic model.  The data was determined based on the TIC data within each ROI (single 
large ROI in the upper portion of kidney).  No significant difference in signal amplitude was 
measured between exposed and buried surface architecture.  In addition, the presence of RGD 
peptide on the surface did not affect the contrast enhancement ability of the microbubbles either. 
 
 The contrast circulation time was characterized by two parameters: persistence half-life 
and 25% time point, which was the time point when the intensity signal dropped down to 25% of 
its maximum amplitude value (Figure 4.11) (Mullin, Gessner et al. 2011).  For the same number 
of microbubbles injected (5×106 #/bolus), ELA Control showed the longest persistence half-life 
with the largest uncertainties (14.6±8.27 min), while BLA Control had a non-statistically 
different persistence half-life (9.36±3.65 min, P = 0.20).  The same trend was found in the signal 
25% time point data (Figure 4.10B) for the control microbubbles.  ELA Control showed the 
longest 25% time (26.0±16.2 min), while BLA Control gave a comparable measurement 
(16.0±6.41 min) with no statistical difference (P = 0.19). 
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Figure 4.11.  Persistence half-life and 25% time point of microbubbles obtained using the one-
compartment pharmacokinetic model.  The half-life (A) was determined from the TIC data at 
which the signal intensity decayed to half of its maximum amplitude, and the 25% time point (B) 
was determined at which the signal intensity decayed to 25% of its maximum amplitude.  
Significant persistence difference was measured between ELA and ELA Control, while BLA and 
BLA Control microbubbles showed similar circulation time.  This data supported the hypothesis 
that the PEG overbrush was able to prolong the microbubble in vivo circulation time. 
 
For the targeted microbubbles, ELA showed significantly reduced persistence half-life 
(4.59±1.11 min) when compared to ELA Control (P < 0.01).  The presence of the RGD peptide 
on the surface shortened the microbubble circulation time by 68%.  The 25% time point for ELA 
microbubbles was shortened significantly as well, down to 7.63±1.78 min, representing a 71% 
decrease when compared to ELA Control. 
On the other hand, targeted BLA microbubbles showed a remarkably similar persistence 
half-life as to BLA Control (8.99±3.32 min) with no statistical difference (P = 0.86), confirming 
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the hypothesis that the buried-ligand architecture protected the RGD peptide from being detected 
by the immune system, and therefore reduced the ligand-induced immunogenicity and prolonged 
the contrast persistence time.  Similarly, the 25% time point for targeted BLA microbubbles did 
not show a difference from BLA Control (15.3±6.56 min; P = 0.84), once again rendering 
support to the protective role of the PEG overbrush. 
 Next, we explored the effect of the total gas volume injected on the signal amplitude and 
persistence half-life (Figure 4.12).  The total gas volume injected was calculated based on the 
volume-weight mean diameter measured by the Multisizer and the total number of microbubbles 
injected.  As expected, all four microbubble groups gave similar total gas volume injected (~0.3 
μL).  There was no obvious relationship observed between either the signal amplitude or the 
persistence half-life and the total gas volume injected over this range. 
 
 
Figure 4.12.  Illustration of the effect of total gas volume injected on signal amplitude and 
persistence half-life.  No correlation was observed for either signal amplitude or persistence half-
life on the total gas volume injected for the microbubble suspensions tested.   
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 Figure 4.13 compares the model fitted parameters C0, k1, k2 and AUC among tested 
microbubble groups.  The C0 parameter (Figure 4.13A) is the fitted initial amount of contrast 
intensity, and is directly related to the signal amplitude shown in Figure 4.10.  It showed an 
identical trend as the signal intensity, with no significant difference detected between control and 
targeted groups, or microbubbles with different surface architectures. 
 The k1 parameter (Figure 4.13B) is the fitted first-order influx rate constant, and is a 
measure of the inflow rate of the contrast agents in the mouse kidney.  No trend was observed 
among the tested microbubble groups with mean k1 values ranging between 1.9 and 2.8 min-1, 
which was as expected since the influx rate depended on the bolus injection speed and the 
spreading of microbubbles in circulation and perfusion into the kidney. 
 The k2 parameter (Figure 4.13C) is the fitted first-order elimination rate constant, and is a 
measure of the clearance rate of the contrast agents in the mouse kidney.  No significant 
difference of the k2 parameter was detected between ELA Control and BLA Control (P = 0.36).  
For targeted microbubbles, ELA showed a significantly higher k2 value when compared to ELA 
Control (P < 0.001), while BLA microbubbles gave a similar k2 value as their BLA Control 
counterparts (P = 0.56). 
The AUC parameter (Figure 4.13D) is the integrated grayscale intensity, and is a measure 
of the total contrast signal enhancement in the ROIs from the microbubbles.  Among the four 
groups tested, ELA Control showed the highest AUC, while ELA gave the lowest, with the mean 
AUC value being only 16% of that calculated for ELA Control.  However, no statistical 
difference was determined between these two groups (P = 0.07) owing to the large variations 
among the calculated AUC values for ELA Control.  On the other hand, BLA Control and BLA 
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microbubbles showed comparable AUC values, and were both statistically similar to that 
calculated for ELA Control (P = 0.30 and P = 0.31, respectively). 
 
4.3.4. Two-Compartment Pharmacokinetic Model 
 For surface-modified microbubbles, it is possible that specific or non-specific interactions 
may result in accumulation of these contrast agents onto the vasculature during imaging.  In 
order to test for this phenomenon, a more sophisticated two-compartment pharmacokinetic 
model was developed by Sirsi et al. (Sirsi, Hernandez et al. 2011) that separates the total 
intensity signal into two subcomponents that describe (1) the signal intensity generated by freely 
circulating microbubbles and (2) the signal intensity generated by passively accumulated or 
adherent, non-circulating microbubbles.  The averaged TICs generated from the multiple smaller 
ROIs in the upper portion of the kidney were used to fit the two-compartment model in order to 
further characterize the circulation persistence of microbubbles with different surface 
architecture designs. 
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Figure 4.13.  Fitted parameters of the TIC data using the one-compartment pharmacokinetic model.  
The parameters were determined using the least square regression analysis.  (A) C0 is proportional 
to the signal amplitude.  Similar to the maximum signal intensity, no significant difference was 
measured across all microbubble samples.  (B) k1 is a measure of the influx rate of the 
microbubbles into the kidneys.  No significant difference was measured across all samples.  (C) k2 is 
a measure of the decay rate of the microbubble signal.  ELA showed significantly more rapid 
contrast elimination when compared to ELA Control, while BLA and BLA Control showed similar 
contrast decay rate.  (D) AUC is a measure of the total integrated contrast enhancement determined 
by the area under the fitted curve.  ELA showed only 16% contrast enhancement when compared 
to ELA Control, though no statistical difference was calculated.  BLA and BLA Control both 
showed more similar contrast enhancement as to ELA Control (45% and 46%, respectively). 
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 Figures 4.14 and 4.15 show a comparison of the two-compartment model fitted 
parameters among the four microbubble groups.  Similar to the result obtained using the one-
compartment model, the fitted C0 parameter (Figure 4.14) once again did not show any 
significant difference between either the control and targeted microbubbles, or microbubbles 
with different surface architectures. 
 
 
Figure 4.14.  Fitted C0 parameter using the two-compartment model.  Similar to the one-
compartment result, no significant difference was detected between either control and targeted 
microbubbles or microbubbles with different surface architectures. 
 
 Analogous to the one-compartment model, the k1 parameter (Figure 4.15A) is the rate 
constant that describes the influx rate of microbubbles into the mouse kidneys upon injection.  
Once again, no statistical difference of the k1 parameter was detected among the microbubble 
groups. 
134 
 
 The k2 parameter (Figure 4.15B) in the two-compartment model is the rate constant that 
describes the elimination of microbubbles from circulation owing to mechanisms other than 
adhesion to the kidney vasculature, such as dissolution, active clearance from the MPS and 
filtering by the liver, spleen and lungs, etc.  No significant difference of the k2 parameter was 
detected between ELA Control and BLA Control (P = 0.52).  For targeted microbubbles, ELA 
showed a significantly faster clearance rate in comparison to ELA Control (P < 0.05), once again, 
indicating ligand-induced elimination.  On the other hand, BLA microbubbles had a similar k2 
value as their BLA Control counterparts (P = 0.30). 
 The k3 parameter (Figure 4.15C) is the rate constant that describes the elimination of 
microbubbles from circulation due to passive accumulation or non-specific adhesion.  No trend 
was observed among the four groups with mean k3 values ranging between 0.02 and 0.11 min-1. 
 Finally, the k4 parameter (Figure 4.15D) is the rate constant that describes the elimination 
of adherent microbubbles from the kidney vasculatures.  Since the model assumes irreversible 
accumulation of contrast agents onto to the kidney endothelium, the k4 parameter mainly 
accounts for the dissolution rate of the adherent microbubbles.  No significant difference was 
detected for the k4 parameter, which was expected since microbubble dissolution did not depend 
on their surface architecture or the presence of the targeting ligand. 
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Figure 4.15.  Fitted parameters of the averaged TIC data using the two-compartment 
pharmacokinetic model.  (A) k1 is a measure of the influx rate of microbubbles into the kidney.  No 
significant difference was detected among the four groups.  (B) k2 is the microbubble elimination 
rate due to mechanisms other than accumulation onto the kidney vasculature.  ELA showed 
significantly faster clearance rate than ELA Control, while BLA showed comparable k2 values as 
BLA Control.  (C) k3 is the adhesion rate constant of microbubbles “stuck” at the kidney 
vasculature.  No significant difference was observed among the groups.  (D) k4 is the microbubble 
dissolution rate constant.  No significant difference was detected among the groups. 
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4.4. Discussion 
 Size-selected microbubbles with different surface architectures were used for in vivo 
ultrasound imaging to study their contrast enhancement ability in mouse kidneys at 40 MHz.  
Two surface architectures were designed and tested: exposed- and buried-ligand architectures 
(Figure 4.1), and RGD peptide was conjugated to the microbubble shell as the targeting ligand to 
simulate molecular imaging applications. 
 Two sets of ROIs were drawn for analysis following two different selection criteria.  On 
one hand, a single large ROI was selected in the upper portion of the kidney (Figure 4.4B) in 
order to detect the maximum increase of signal enhancement while the potential for 
microbubble-induced attenuation was minimized.  Microbubble-induced attenuation is undesired 
because it artificially reduces the contrast enhancement during imaging.  Therefore, it is 
important to minimize signal attenuation during quantitative contrast flow measurements.  On 
the other hand, multiple smaller ROIs were drawn across different regions of the kidney (Figure 
4.4C), and their measured signal intensities were averaged to represent the total change of the 
entire tissue.  Sirsi et al. (Sirsi, Feshitan et al. 2010) reported that microbubble shadowing was 
observed in the lower region of mouse kidneys after bolus injections of 1-2 μm microbubbles 
with similar lipid compositions, but at a higher concentration.  The present data confirmed their 
findings by showing that the TICs generated using the lower ROIs (red ROIs in Figure 4.4C) had 
significantly reduced maximum signal intensities than those generated using the upper ROIs 
(white ROIs in Figure 4.4C), indicating microbubble shadowing.  Therefore, only the upper 
portion of the mouse kidneys was selected for data analysis. 
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 Previous studies have demonstrated that microbubble size and concentration strongly 
affect their acoustic behavior and contrast persistence (Talu, Hettiarachchi et al. 2007; Kaya, 
Feingold et al. 2009; Sirsi, Feshitan et al. 2010).  To eliminate these effects, only size-isolated 
microbubble suspensions with the same concentration were used for the study.  Large 
microbubbles have been shown to produce higher contrast enhancement with longer circulation 
persistence than the smaller ones (Sirsi, Feshitan et al. 2010; Streeter, Gessner et al. 2010).  
Because 4-5 μm microbubbles are presented in a freshly generated suspension with relatively 
higher concentration than 6-8 μm ones, they were chosen to be used as the size-selected sample 
for all injections (Feshitan, Chen et al. 2009).  The perfusion data confirmed the size and 
concentration dependence by showing that all microbubble samples had similar contrast 
enhancement in the mouse kidneys regardless of their surface architecture or targeting ligand 
presentation (Figure 4.10). 
 A similar trend was observed for the effect of total gas volume injected on microbubble 
contrast enhancement and persistence based on data fitting using the one-compartment model 
(Figure 4.12): no correlation was found between either the signal amplitude or the persistence 
half-life and the total gas volume injected.  This was expected since the total gas volume 
depended on the size distribution and concentration of the injected microbubble suspension.  
Sirsi et al. (Sirsi, Feshitan et al. 2010) have previously pointed out that the amount of contrast 
enhancement was not determined by the volume of gas that was injected, but rather how the gas 
was distributed within the microbubbles.  Here, further evidence was shown, lending support to 
this conclusion (Figure 4.12). 
 On the other hand, the microbubble surface architecture affected their circulation 
persistence significantly (Figure 4.11).  ELA Control showed significantly longer persistence 
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(both half-life and 25% time point) than ELA microbubbles, while BLA Control and BLA 
microbubbles had similar circulation time.  The presence of RGD peptide on the surface of ELA 
microbubbles clearly shortened their persistence, and this was believed to be caused by the 
ligand-induced complement activation (see Chapter 3).  Similar results were previously reported 
to link increased complement activation to increased elimination rate of liposomes from blood 
circulation (Ishida, Kojima et al. 2000; Huong, Ishida et al. 2001).  The present data supported 
the hypothesis that the buried-ligand architecture could protect the targeting ligand from 
exposure to the surrounding environment and therefore prolonged the microbubble persistence 
by reducing their immunogenicity.  The contrast elimination was further explored by fitting the 
TIC data to the one-compartment pharmacokinetic model and evaluating the k2 parameter 
(Figure 4.13C).  Significant faster elimination rate was observed for ELA microbubbles than 
ELA Control, while no difference was detected between BLA and BLA Control. 
 A more sophisticated two-compartment model was also used to further differentiate the 
mechanisms of microbubble clearance during circulation (Figure 4.15).  The value of k2 
parameter (Figure 4.15B), the elimination rate of contrast signal from circulation, was 
significantly higher for ELA microbubbles compared to ELA Control, once again, indicating that 
targeted ELA microbubbles were cleared from the system much faster.  More importantly, no 
significant difference was detected in the value of k3 parameter (Figure 4.15C), the rate at which 
microbubbles became adherent in the kidney, in comparison to ELA Control.  This result 
clarifies that the reason of the fast clearance for ELA microbubbles was not due to passive 
accumulation or non-specific adhesion, but rather caused by other mechanisms, such as active 
clearance by the MPS.  On the other hand, the total elimination rate of BLA microbubbles was 
not increased due to the presence of the RGD peptide in comparison to BLA Control.  Once 
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again, these results were consistent with the protective role of the PEG overbrush.  It is important 
to note that targeted BLA microbubbles could potentially trigger complement activation while 
remaining long circulating.  It is possible that the complement immune system was still activated 
after injection.  However, the presence of the PEG overbrush physically inhibited the 
accessibility of macrophages to the opsonins and thus protected the contrast agents from 
elimination. 
It has been reported that repeated injection of “empty” PEGylated liposomes led to 
accelerated blood clearance phenomenon of the second dose of liposomes even when the 
injections were spaced by a few days (Ishida and Kiwada 2008).  Interestingly, the same 
phenomenon was not observed in the present experiment when control microbubbles (ELA or 
BLA) were injected in the “pre-exposed” mice with only one day apart.  This may be explained 
by several factors.  First, PEGylated liposomes can circulate in blood on the order of days, much 
longer than microbubbles.  This gives them more chance to be in contact with the MPS for 
potential immune recognition.  Second, the current microbubble injections were repeated in the 
same animal only one day apart.  This short “resting” period might not be enough for the 
production of antibodies for microbubble elimination before the second injection was given.  A 
longitudinal study will be required, however, in order to fully understand the impact of repeated 
injection of targeted contrast agents on their circulation persistence. 
The buried-ligand architecture design clearly improved the circulation persistence of 
targeted contrast agents when compared with the exposed-ligand architecture design (68% 
reduction in persistence half-life for ELA microbubbles in comparison with 4% reduction for 
BLA microbubbles based on results shown in Figure 4.11A).  When combined with USRF, the 
stealth microbubble construct offers both spatial and temporal control of selective adhesion 
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(Borden, Zhang et al. 2008).  By utilizing BLA microbubbles for targeted molecular imaging 
applications, the need for dwell time after injection can be potentially eliminated because of the 
triggered binding at the targeted site.  In addition, BLA microbubbles showed longer circulation 
persistence, which could increase the binding efficiency since the probability of targeted 
adhesion is directly proportional to the number of passes of microbubbles through the circulatory 
system.  Since there seems likely to be a tradeoff between the imaging wait time and binding 
efficiency, using size-selected BLA microbubbles for targeted molecular imaging applications 
could potentially improve the imaging protocol significantly. 
 
4.5. Conclusion 
 Microbubbles with various surface architectures were generated and size selected using 
the differential centrifugation technique.  RGD peptide was conjugated to the surface as the 
targeting ligand using a post-labeling technique.  The contrast enhancement and circulation 
persistence of these microbubbles were delineated from images of the mouse kidneys using a 
high frequency ultrasound scanner at 40 MHz.  For the same injected concentration, 
microbubbles with various surface architectures produced similar contrast enhancement 
regardless of the presentation of the targeting ligands on the surface.  However, their contrast 
persistence was highly affected by the PEG brush architecture.  Targeting ligand inducing 
complement activation resulted in shortened circulation time for ELA microbubbles significantly 
when compared to ELA Control (68% reduction in persistence half-life).  On the other hand, the 
buried-ligand architecture successfully protected the RGD peptide from exposure to the 
surrounding environment and thus prolonged the bloodstream persistence, as evidenced by the 
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almost identical persistence time.  No accelerated blood clearance phenomenon was observed for 
repeated microbubble injections in pre-exposed mice when the injections were only one day 
apart.  The data presented here could potentially change the protocol of targeted molecular 
imaging when the stealth microbubble design is utilized. 
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Chapter 5: Concluding Remarks and Future Directions 
 
5.1. Accomplishment of Specific Aims 
5.1.1. Ligand Conjugation to Bimodal PEG Brushes on Microbubbles 
 The difference between ligand diffusion and binding to the monolayer shell of 
microbubbles was studied using various poly(ethylene glycol) (PEG) brush architectures, ligand 
sizes and binding modes.  Microbubbles were pre-formed using high-speed amalgamation 
technique, and two fluorescently labeled ligands with vast molecular weight difference were 
conjugated to the microbubbles. The ligand diffusion and binding rate was monitored by 
measuring the median fluorescence intensity change over time using flow cytometry. 
 Two binding phenomena were observed.  For microbubbles with a bimodal PEG brush 
layer on the surface, the diffusion and conjugation of small molecules, such as NHS-FITC with 
molecular weight <1 kDa, was not affected due to the PEG overbrush.  The ligand binding 
kinetics was the same between ELA and BLA microbubbles.  On the other hand, for 
macromolecules, such as SA-FITC with molecular weight >10 kDa, the diffusion and binding 
rate was significantly changed: BLA microbubbles showed a much slower binding kinetics than 
their ELA counterparts.  This phenomenon was believed to be caused due to the steric hindrance 
effect of the flexible PEG chains.  The diffusion of macromolecules was partially inhibited 
because of the excluded volume of the PEG brushes.  The binding of SA-FITC to BLA 
microbubbles suggested a possible phase separation between lipid species on the monolayer 
surface, leading to populations of revealed and concealed ligands.  In addition, flow cytometry 
allowed the binding kinetics data to be analyzed based on microbubble size.  It was found that 
143 
 
 
ligand conjugation kinetics was independent of microbubble size, regardless of ligand size or 
microbubble architectures.  These results demonstrated the feasibility of post-labeling for small 
ligands to BLA microbubbles to generate stealth targeted ultrasound contrast agents. 
 Epi-fluorescence microscopy was utilized to visually confirm ligand conjugation to the 
surface of microbubbles.  Streptavidin-induced structure formation (e.g., folds and protrusions) 
on ELA microbubbles was observed for the first time.  Instead of using mechanical 
pressurization, complex surface structures were obtained simply through multivalent ligand 
binding.  It was proposed that this phenomenon may be correlated to flow cytometry scattering 
measurements. 
 
5.1.2. Microbubble-Induced Complement Activation In Vitro 
 The role of PEG brush architectures on microbubble-induced complement activation in 
vitro was studied using human complement-preserved serum.  The post-labeling technique was 
utilized to generate targeted ELA and BLA microbubbles with various PEG brush architectures 
using RGD peptide conjugated to the surface as the targeting ligand, and the degree of 
complement activation was quantified by measuring complement C3/C3 binding using flow 
cytometry. 
The stability of microbubbles in human serum was examined, and it was shown that 
microbubbles, regardless of their surface architecture or the presence of targeting ligands, were 
stable for at least 2 hrs at physiological conditions.  Human serum factor binding test showed 
that complement component C3/C3b, in comparison to human serum albumin and 
immunoglobulin G, was the only protein that significantly bound to targeted microbubbles.  For 
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ELA microbubbles, complement C3/C3b binding was directly correlated to the amount of RGD 
peptide on the surface: increased amount of RGD induced more complement C3/C3b binding.  
On the other hand, this direct correlation was not observed for BLA microbubbles: when the 
amount of RGD peptide was increased by 2 orders of magnitude, no significant increase of 
complement C3/C3b binding to BLA microbubbles was measured.  The amount of C3/C3b 
binding was also proportional to microbubble surface area: larger targeted microbubbles induced 
more complement activation.  This most likely was due to the increased RGD peptide 
presentation on the surface as well.  Control microbubbles without any targeting ligand showed 
complement C3/C3b binding too, though the amount was much less when compared to targeted 
microbubbles.  This finding suggested that the underlying phospholipid species could trigger 
complement recognition and induce potential immune response.  The effect of the surface 
architecture on complement activation was further studied by comparing C3/C3b binding to 
targeted microbubbles with the same amount of RGD conjugated to the surface but with different 
PEG brush heights.  It was found that the PEG brush height is directly correlated to complement 
binding: the higher the PEG overbrush, the more it could shield the targeted ligand from 
exposure and thus reduce complement recognition.  Finally, the effect of microbubble surface 
charge was investigated, and it was shown that the negative charge on the microbubbles induced 
complement C3/C3b binding.  This data supported the notion that the negative charge associated 
with the phosphate group in DSPE-PEG2000 played a critical role in complement activation. 
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5.1.3. Targeted Microbubble In Vivo Perfusion Imaging 
 The contrast enhancement and circulation persistence of targeted microbubbles with 
various surface architectures was studied in mouse kidneys using a high frequency ultrasound 
scanner with a 40 MHz transducer.  Similar to the previous experiments, microbubbles were pre-
formed and the RGD peptide was conjugated to the microbubble surface using a post-labeling 
technique.  Because of the strong dependence of microbubble acoustic properties on the 
diameters, 4-5 μm size-isolated microbubbles were used for this study.  In order to avoid 
complement activation induced by repeated microbubble injections, only one bolus injection was 
done per animal per day.  A one-compartment pharmacokinetic model was used to fit the 
contrast intensity data in order to quantify signal enhancement and circulation time.  It was found 
that the contrast enhancement of microbubbles was not affected by their PEG brush architectures 
or the presence of targeting ligands on the surface.  The ability of microbubbles to increase the 
contrast of ultrasound images was only dependent on their size distribution and concentration.  
However, the persistence half-life was strongly affected by the PEG overbrush: ELA 
microbubbles showed a significantly reduced circulation time when compared to ELA Control, 
while BLA and BLA Control showed comparable persistence half-lives.  This data suggested the 
ability of the buried-ligand architecture to prolong targeted microbubble bloodstream circulation 
by inhibiting complement recognition and surface fixation.  These findings strongly supported 
the hypothesis that targeted microbubbles with the buried-ligand architecture could reduce the 
immunogenicity and prolong their circulation persistence without compromising their contrast 
enhancement ability. 
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5.2. Impact on the Field 
 Previous studies have suggested that polymer brushes could retard the diffusion of large 
molecules to the PEG grafted surface due to their excluded volume.  This effect has become the 
design base of long circulating Stealth liposomes and many other colloidal particles.  Following 
the same principles, PEG chains are incorporated into the monolayer shell of microbubbles in 
order to form a steric barrier against coalescence and macromolecule surface adsorption.  
However, for targeted molecular imaging applications, the surface functionalization is typically 
done by conjugating the targeted ligands at the distal end of the PEG chains, and the presence of 
these specific ligands on the surface could trigger immune response and decrease their 
circulation time.  In order to avoid these undesired effects, a bimodal PEG brush layer with the 
buried-ligand architecture (BLA) is designed to generate stealth microbubbles with improved 
binding selectivity, decreased immunogenicity and prolonged circulation persistence. 
 The ligand conjugation study reveals great insight into the role of the PEG brush layer on 
molecular diffusion and binding to the monolayer surface of microbubbles with various surface 
architectures.  The ability to inhibit ligand diffusion and binding by PEG chains has been shown 
previously by Needham et al. (Needham, Zhelev et al. 1999).  The present study, however, shed 
new light on the binding of solutes to tethered groups in various brush architectures on the 
surface of microbubbles.  Evidence is shown to confirm that BLA microbubbles indeed partially 
prevented the binding of macromolecules (molecular weight >10 kDa) to the bimodal PEG 
grafted surface while allowing the uninhibited attachment of small ones (molecular weight < 1 
kDa).  This finding demonstrates the feasibility of utilizing the post-labeling technique for 
generating targeted contrast agents using small ligands, such as peptides, and provides the basis 
for translating this platform strategy for large-scale production of targeted contrast agents.  
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Perhaps more importantly, it provides insights for fundamental tethered ligand-receptor 
interactions at grafted Langmuir-monolayer surfaces.  For example, one could engineer the 
polymer surface coverage density and chain length in order to achieve the desired overbrush 
height so that ligand conjugation is only possible for molecules within a certain size limit.  This 
strategy could be developed to utilize BLA microbubble as a separation platform for selective 
molecular binding in solution. 
The most unexpected result comes from the observation that, for the first time, complex 
microstructures on the surface of microbubbles are induced simply via streptavidin-biotin 
binding.  Fluorescence microscopy provides direct confirmation of these wrinkled structures that 
are normally not detected for microbubbles bound to other small ligands.  Furthermore, the 
percentage of microbubbles in a given suspension that deviate from the normal spherical shape 
can be quantified using flow cytometry. 
 The in vitro immunogenicity and in vivo contrast persistence experiments are the next 
steps in showing the advantage of having the buried-ligand architecture as the stealth 
microbubble design over the exposed-ligand architecture (ELA).  By measuring the binding of 
complement component C3/C3b to targeted microbubbles in vitro, complement activation is 
quantified.  The study clearly shows the correlation between targeting ligand concentration and 
complement activation: the higher RGD peptides are presented on the surface of microbubbles, 
the more C3/C3b binding occurs.  However, this phenomenon is not observed for BLA 
microbubbles, suggesting the ability of the PEG overbrush to shield the targeting ligand from 
exposure to the surrounding environment and therefore decrease the microbubble 
immunogenicity.  This protective role is further illustrated by tailoring the length of the PEG 
chains and showed that complement activation is directly related to the PEG overbrush height.  
148 
 
In the in vivo experiments, by measuring the contrast persistence of targeted microbubbles with 
various PEG brush architectures in mouse kidneys, it is clearly shown that BLA microbubbles 
are more stable during circulation in comparison to their ELA counterparts.  This work provides 
the most direct confirmation of the advantage for utilizing BLA design to generate stealth 
microbubbles for targeted molecular imaging applications. 
 
5.3. Future Directions 
 The most obvious extension of the present work is to study the effect of the buried-ligand 
architecture on microbubble contrast persistence in vivo longitudinally.  In order to translate the 
stealth BLA microbubble design for molecular imaging studies, it is extremely important to 
know the “long term” effect of the targeted microbubbles since repeated injection is most likely 
required for these applications.  A direct comparison between ELA and BLA microbubble 
circulation persistence after repeated injections in both healthy and diseased animal models could 
provide further evidence to support the utilization of BLA design to generate targeted ultrasound 
contrast agents. 
 Furthermore, it is relevant to study the adhesion efficiency of targeted BLA microbubbles.  
It is essential to create a stealth targeted contrast agent on which the ligand does not increase 
complement activation or other immunogenic factors.  Yet, it is equally important to show that 
the contrast agent could firmly adhere to a target site with high selectivity and remains echogenic 
for subsequently imaging.  In addition, the effect of the ultrasound radiation force on BLA 
microbubbles adhesion to target sites during shear flow needs to be studied as well in order to 
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optimize the acoustic parameters for transient activation of these stealth microbubble contrast 
agents.  
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